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ABSTRACT 
 
 The RNA recognition motif (RRM) is the most abundant RNA binding domain that is 
found in all organisms.  RRM-containing proteins participate in most steps of gene expression, 
including translation, splicing, modification and transport of RNA.  This dissertation aims to help 
understand the interactions of the RNA recognition motif and RNA by developing a small 
molecule modulator of the interaction and analyzing the kinetics of dissociation.  The first 
chapter gives an introduction to the function and structural characteristics of RNA binding 
proteins, RNA recognition motifs and two RRM proteins, U1A and Sex lethal protein.  Chapter 2 
describes the identification and analysis of three small molecules that disrupt two different 
RRM-RNA complexes, Sex lethal protein-tra RNA and U1A-SL2 RNA.  The research discussed 
in chapter 3 focus on the role of positively charged residues in the U1A protein and SL2 RNA 
complex dissociation process.  Analysis of kinetics data obtained by temperature jump and 
stopped-flow experiments showed that the location of the electrostatic interaction controls the 
rate of different steps in the complex dissociation pathway.  Chapter 4 is a description of a 
simple and rapid method to detect RNA splice variants using biarsenical dyes and split 
tetracysteine moieties, which may accelerate biochemical studies of alternative splicing and 
identification of factors that modulate RNA splicing.  
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CHAPTER 1 
RNA Binding Proteins and RNA Recognition Motif 
 
1.1 RNA binding proteins (RBPs) 
 RNA is a highly versatile molecule that plays a fundamental role in all living organisms.  
Its functions range from being a messenger of genetic information encoded by DNA to the 
regulations of essential cellular processes.1-4  In most cases, these functions are carried out in 
close association with RNA-binding proteins.4-7  RNA binding proteins (RBPs) bind to RNA as 
soon as RNA is transcribed and regulate RNA metabolism including pre-mRNA splicing, 
polyadenylation, mRNA export, nonsense mediated decay and protein translation.5,6  Several 
RBPs may interact with RNA to form functional units called ribonueloprotein (RNPs) or may 
individually bind to cis-acting elements of the RNA.  There are several hundred RBPs in humans 
and this number is likely to increase with advanced genetic, biochemical and computational 
methods.8	   	   The most prominent structural feature of RBPs is that they contain RNA binding 
domains as well as auxiliary domains that mediate protein-protein interactions or catalytic 
activity.  
 
1.1.1 Functional diversity of RNA binding proteins 
 From genomics to proteomics, RNA binding proteins (RBPs) play an essential role in 
gene expression and gene regulation at various levels (Figure 1.1).6,9,10  Many RBPs carry out a 
wide variety of functions by forming ribonucleoprotein complexes (RNPs).  RNPs are highly 
dynamic as different RBPs bind and dissociate at different stages during post-transcriptional 
processes.   Depending on where and when the RBPs associate with the RNA transcript, they are 
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classified differently.  The primary protein-coding transcripts that are produced by polymerase II 
are termed pre-mRNA or heterogeneous nuclear RNAs  (hnRNPs).  Therefore proteins that bind 
to pre-mRNA in the nucleus are termed hnRNP proteins.5  On the other hand, proteins that bind 
to mature RNA messages in the cytoplasm are termed mRNP proteins.  However this 
nomenclature is not necessarily accurate since some RBPs are bound before and after RNA 
splicing and can shuttle between nucleus and cytoplasm.  hnRNP and mRNP proteins participate 
in transcriptional regulation, biogenesis of telomere, immunoglobin gene recombination, splicing, 
pre-ribosomal-RNA processing, 3' end maturation, nucleo-cytoplasmic transport of mRNA, 
cytoplasmic localization, translation, and stability.5,11  
 Non-coding RNAs play a significant role in numerous cellular processes.  ncRNAs in 
complex with RNA binding proteins form various RNPs.  These RNPs function on many target 
RNAs including mRNA, ribosomal RNA, snRNAs, and tRNA.4  The small nuclear (sn)RNPs 
and small nucleolar (sno) RNPs are the most studied ncRNPs.  snRNPs form the core of 
spliceosome with the exception of U7 snRNP, which is involved in histone pre-mRNA 3' end 
formation.  snRNPs are composed of U snRNA (U1, U2, U4, U4atac, U5, U7, U11 or U12), a 
heptameric ring of Sm proteins and other proteins specific to each snRNP.  snRNP proteins are 
responsible for the biogenesis, nuclear export, and the activity of the snRNPs.   
 While there are less than a dozen snRNAs in eukaryotic cells, there are more than 200 
unique snoRNAs.12  snoRNAs guide the modification of nucleotides by base-pairing to the target 
RNAs.13  Based on the conserved sequence elements, snoRNAs are divided into two major 
families, the C/D and H/ACA RNAs.  All of the RNAs of each family bind to a distinct set of 
highly conserved RBPs to form C/D RNPs and H/ACA RNPs.  The primary function of C/D 
RNPs is to methylate the 2'-OH group of target nucleotides, whereas H/ACA RNPs convert 
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uridine to pseudouridine.  Dyskerin directly binds to H/ACA RNA through its RNA binding 
domain and mediates pseudouridylation of rRNAs and snRNAs.  For C/D RNPs, L7Ae binds to 
the C/D RNA and creates another binding site for the NOP56 protein.  NOP56 in turn recruits the 
catalytic protein fibrollarin, which is responsible for the 2'-O-methylation of nucleotides.4  Most 
snoRNPs modify other ncRNAs including rRNA, snRNA, tRNA.  However at least one pre-
mRNA was found to be targeted by C/D RNP.  The brain specific C/D snoRNA, HBII-52 binds 
to the pre-mRNA of seratonin receptor and regulates alternative splicing.14  Another interesting 
target of snoRNP is the telomere.  Telomerase RNA is a type of H/ACA RNA which forms a 
telomerase complex.  Telomerase reverse transcriptase (TERT) is the RBP in the complex that 
extends the ends of chromosomes.  Targets of a large number snoRNAs remain to be discovered.  
Identification of the substrates of snoRNPs might further expand the function of snoRNPs. 
 RBPs regulate biogenesis, localization, degradation, and the activity of microRNAs, 
which in turn repress gene expression by interacting through the 3' UTR of mRNAs.15  
Transcribed miRNAs are processed by Drosha and then exported to the cytoplasm by Exportin 5 
and RAN-GTP.  In the cytoplasm, they are further processed by Dicer and HIV-1 transactivating 
response RNA binding protein (TRBP).  Argonaute protein is recruited by TRBP and the 
miRNA eventually forms the miRNA-induced silencing complex (miRISC), also called the 
miRNA ribonucleoprotein complex (miRNP).  miRNP consists of miRNA, Ago protein and 
another RNA binding protein, GW182.  This complex is responsible for the translational 
inhibition of various mRNAs.  Other than snRNPs, snoRNPs and miRNPs, there are many 
ncRNPs that function in diverse biological processes: pre-tRNA maturation by RNase P, 
transcription elongation by 7SK RNP, protein translocation to the endoplasmic reticulum by SRP 
RNP etc.4  
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Figure 1.1  The function of RBPs in multiple cellular processes.  Nascent transcripts that are 
produced by RNA polymerase II are recognized by diverse RBPs such as hnRNP proteins and 
SR (serine/arginine-rich) proteins.  Pre-mRNA splicing is carried out by uridine-rich small 
nuclear RNPs (U snRNPs) that make up the spliceosome.  Spliced mRNAs are associated with 
RBPs that are organized into a complex near exon-exon junctions (EJC).  EJC proteins direct the 
export, cytoplamic localization or non-sense mediated decay (NMD) of mRNAs.  Histone 
mRNAs are processed by U7 snRNP.  Telomerase is a ribonucleoprotein enzyme that replenishes 
the terminal telomeric repeats of chromosomes. Small nucleolar RNPs (snoRNPs) mediate 
maturation of ribosomal RNAs.  In cytoplasm, ribosomes translate mRNA into proteins.  It also 
functions with the signal recognition particle (SRP) RNP to carry proteins into the endoplasmic 
reticulum (ER).  MicroRNAs interact with RBPs to regulate transcription, mRNA stability and 
translation.6 
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1.1.2 RNA binding domains 
 RBPs have a modular structure and contain RNA binding domains that mediate RNA 
recognition (Figures 1.2 and 1.3).  Most RBPs consist of multiple copies of RNA binding 
domains presented in various structural arrangements to specifically bind to diverse RNA 
substrates.  RNA binding domains of the same or different structural types are connected with 
linkers to form a large binding surface, which allows the protein to recognize a longer stretch of 
RNA.  This modularity also enables the protein to bind to sequences that are separated by an 
intervening stretch of nucleotides.   
 
 
Figure 1.2  Structure of RNA binding domains in complex with RNAs.  RNAs are highlighted in 
yellow, α-helices are colored blue, and β-sheets are in light blue. pdb codes for each domains are: 
RRM (1URN), KH (1EC6), dsRBD (1T4L), ZnF (1RGO), PAZ (1SI3).  These structures were 
generated with the program Chimera.16 
 
 To date, 40 different types of domains that are involved in RNA recognition are 
identified and the number is constantly increasing.9  Some well-characterized RNA binding 
domains include the following: RNA recognition motif (RRM, RBD or RNP), K-homology (KH) 
domain, double-stranded RNA binding domain (dsRBD), Zinc finger, PIWI/Argonaute/Zwille 
	   6	  
(PAZ) domain, and Pumilio domain.  The topology, primary RNA recognition mode, and type of 
protein-RNA interactions of these RNA binding domains are listed in Table 1.1.  The RNA 
recognition motif is the most abundant RNA binding domain and will be discussed in more detail 
in section 1.3.  
 
Figure 1.3  Modular structure of RBPs.  RBPs are built from RNA binding motifs.  Some RBPs 
also contain auxiliary motifs, which mediate protein-protein interactions (e.g. RS domain) or 
catalytic activity (e.g. kinase, endonuclase, helicase and deaminase).17 
 
 RBPs frequently contain domains that mediate protein-protein interaction or catalytic 
activity.  Proteins that assist spliceosomes in splice site selection such as splicing factors and 
hnRNPs contain arginine/serine-rich (RS) domains, which participate in protein-protein 
interaction.  Some RBPs contain enzymatic domains, including kinase, helicase, endonuclease, 
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and deaminase.  RNA binding domains locate and in some cases regulate the activity of these 
catalytic domains.  For instance, Drosha and Dicer position the two catalytic RNase III domains 
using RNA binding domains.  In protein kinase PKR and the RNA-editing enzyme ADAR2, 
RBDs interact with the catalytic domain to maintain the inactive state.  Upon RNA recognition 
the catalytic domain is released and activated.  
 
Table 1.1  RNA recognition of common RNA binding domains (RBDs).17 
  
 
1.2 RNA recognition motif (RRM) 
 The RNA recognition motif (RRM, also known as RBD or RNP motif) is the most 
abundant and best characterized RNA binding domain.18  It is found in all life kingdoms, 
including prokaryotes and viruses although it is most prevalent in eukaryotes.  According to the 
Pfam database, more than 30,000 sequences have been identified to encode RRM.  RRMs have 
	   8	  
been implicated in various cellular functions including spliceosome assembly,19 RNA chaperone 
activity,20 and telomere biogenesis.21  The RRM is composed of approximately 90 amino acids 
and is structurally characterized by a typical βαββαβ-fold.  Structural and biochemical studies 
have shown that RRM is a simple, but highly versatile, protein motif that can bind to not only 
RNA but also DNA and proteins, reflecting its functional diversity. 
 
1.2.1 Primary binding mode of RRM 
  The RRM is comprised of about 90 amino acids that fold into an antiparallel β-sheet 
flanked by two α-helices with a β1α1β2β3α2β4 topology (Figure 1.4).  RRMs typically bind to 
single-stranded RNA in a variety of structural contexts.  Recognition of RNA by RRMs relies on 
a combination of stacking interactions, hydrogen bonds, van der Waals contacts, and salt bridges.  
Based on the structural analysis of many RRM-nucleic acid complexes, common themes of 
RRM-nucleic acid interaction have been described.  Two examples of RRMs, hnRNPA1 RRM2 
and polyadenylate binding protein (PABP), in complex with DNA and RNA, respectively, are 
shown in Figures 1.4a and b.  The beta sheet is the primary surface for single-stranded nucleic 
acid recognition.  The RRM has two consensus sequences, RNP1 and RNP2, in the β3 and β1 
strands, respectively (Figure 1.4c).  In both structures, three positions of the RNP1 and RNP2 
have aromatic residues (position 2 of RNP2, position 3 and 5 of RNP1).  Two of the aromatic 
residues (position 2 of RNP2 and position 5 of RNP1) form stacking interaction with the RNA 
bases.  The third aromatic residue located on β3 (position 3 of RNP1) has different roles in RNA 
recognition between the two complexes.  In hnRNPA1 this residue interacts hydrophobically 
with sugar rings of the RNA.  In PABP, the hydroxyl group of Tyr54 forms electrostatic 
interactions with the phosphate backbone of A8 and the 2'-OH group of A7 of the RNA.  Within 
	   9	  
the consensus sequence this variation in the mode of binding is rather common.  This trend is 
also found with the first residue of RNP1.  In many RRM proteins, this residue is an arginine or a 
lysine that contacts an RNA base or a phosphate oxygen of other nucleotides.  In hnRNPA1 this 
residue is an arginine that forms a salt bridge with the phosphate between A203 and G204.  
However, this residue in PABP is a leucine that forms van der Waals interactions with the A7 of 
the RNA.  
 
 
Figure 1.4 The interaction of the β-sheet surface of the RRM with a single-stranded nucleic acid. 
a) RRM2 of hnRNP A1 protein bound to telomeric DNA (pdb: 2UP1).  b) RRM1 of PABP 
bound to polyadenylate RNA (pdb: 1CVJ). Nucleotides are shown in yellow, α helices of the 
protein in blue, β-sheet in light blue, and other regions of the protein in grey. These structures 
were generated with the program Chimera.16  c) Consensus sequences of RNP1 and RNP2 and 
the scheme of the four β-sheets with the conserved residues highlighted in orange. X can be any 
amino acid.18  d) A linear scheme of the secondary structure. L is loop. 
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 As exemplified with hnRNP A1 and PABP, most RRMs form at least two stacking 
interactions with RNA using two of the three conserved aromatic residues.  These π-π stacking 
interactions are critical for the binding affinity of the RRM to the RNA.  The substitution of one 
of these residues for an alanine results in a 100,000 fold decrease in binding affinity in U1A 
(F56A)22 and 30,000 fold decrease in binding in Fox-1 (F160A).23 This basic binding platform 
common to all RRMs, has a minimal role in sequence-specificity of the RRM.  Eight of the 16 
possible dinucleotide combinations have already been found to be recognized by proteins 
containing RRMs, indicated in parenthesis: AA (PABP), AG (hnRNP A1), CG (nucleolin), CA 
(U1A), GU (Sex lethal), UC (nucleolin), UG (Fox-1) and UU (Sex lethal).18  Specificity of RNA 
recognition is provided by other residues in the consensus sequence and non-conserved elements 
of the RRM, mostly via base specific hydrogen bonds. 
 
1.2.2 Role of other regions in binding 
 Other than the primary binding mode that uses the two aromatic residues for stacking 
interactions, the binding pattern is significantly different from one RRM to the other.18,24  This 
variation in binding mode explains how this structurally conserved motif can bind to different 
nucleic acid targets.  The two external β-strands (β2 & β4), loops, N-terminal region, and C-
terminal region may be utilized to different extents for target recognition.  For example, in 
RRM1 of hnRNPA1, the β4 and the β2 each interact with one nucleotide,25 while most RRMs do 
not use these β-strands to contact nucleotides.18     
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Figure 1.5  Role of other regions in RNA binding.  a) N-terminal RRM of U1A bound to SL2 
RNA (pdb:1URN).  b) Fox-1 bound to 5'-UGCAUGU-3' RNA (pdb: 2ERR).  c) CBP20 bound to 
7-methyl guanosine cap (m7GpppG) (pdb:1N52). d) RBD1 of Musashi1 bound to numb RNA 
(pdb: 2RS2).  These structures were generated with the program Chimera.16 
 
 In many cases, loops connecting the β-strand and the α helix are crucial for nucleic acid 
recognition.  For example, loop 3 of the N-terminal RRM of U1A is crucial for the recognition of 
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stem loop 2 RNA.  Several hydrophobic contacts are made to insert the loop into the RNA stem 
loop and a critical residue, Arg52, forms hydrogen bonds with A6 in the loop of the RNA and 
G16 of the GC stem (Figure 1.5a).  Arg to Gln mutation at this position completely abolishes 
binding affinity to the RNA.26  Another RRM protein, Fox-1 has a phenylalanine residue in loop 
1 that forms a stacking interaction with the base of U197 (Figure 1.5b).23  Mutation of this 
residue to an alanine resulted in a 1,500-fold decrease in binding affinity, which is comparable to 
the amount of decrease that is found with an aromatic residue of one of the RNP sequences is 
mutated to an alanine.  This type of aromatic residue is found in several other RRMs including 
REF2-I but is not a general feature of RRMs.   
 In an extreme case, the β-strands are not used to bind RNA and the binding is primarily 
accomplished by the loops.  This was found in three RRMs of hnRNP F, which lack the 
conserved aromatic residues in the RNP.27  These RRMs have been renamed quasi RRMs.  Cléry 
et al. have suggested that quasi RRMs may have appeared later in evolution in order to expand 
the range of RNA target sequences that can be bound by an RRM.24 
 N-terminal and C-terminal regions often interact with the RNA and enhance the RNA-
binding affinity.  In many RRM-RNA complexes, the base stacking on the aromatic residue at 
position 2 of RNP2 is sandwiched either by a protein side chain from the N-terminal region or by 
one from the C-terminal region (Figure 1.5c and d).  In some RRMs, the C-terminal region 
contains a short α helix.  This C-terminal helix (helix C) in free U1A protein is contacting the β-
strand surface where the RNA binds.28  In the process of RNA binding, helix C moves away 
from the β-surface and stays away in the complex.  The bound conformation allows the RNA to 
contact the primary β-surface and form various contacts with the helix C including stacking 
interaction of Asp92 with C12 (Figure 1.5a).26  Helix C of U1A is thought to contribute to the 
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specificity of the RRM through participation in dynamical processes.29,30  In another protein 
CstF-64, the helix C unfolds upon binding and does not have any direct contact with the 
RNA.31,32   
 
1.2.3 Recognition of RNA over DNA 
 RRMs usually interact with single stranded RNA, but they are also known to interact 
with single stranded DNA.24  Some RRMs have a much higher binding affinity to the single 
stranded RNA compared to the same sequence of single stranded DNA as found in Sex lethal 
protein and Polyadenylate binding protein (PABP).33-35  Other RRMs, such as hnRNP A1, bind 
specifically and with high affinity to both DNA and RNA of similar sequences.25  RRMs that 
specifically recognize single stranded RNA form hydrogen bonds with the 2'-OH group of the 
sugar ring with the side chain or the amide group of the backbone.  These hydrogen bonds are 
mediated by various parts of RRM including C-terminus, β-strands and the loops.  Other than the 
direct protein-RNA contacts, indirect effects through structural requirements for the RNA may 
also play an important role in RNA recognition.  For example, when tra RNA is bound to Sex 
lethal it forms a kink in the middle, which is mediated by three internucleotide hydrogen bonds 
between the 2'-OH groups and phosphate groups of the RNA.36 
 
1.2.4 Proteins with multiple RRMs 
 Most RRM proteins contain multiple RRMs. While some proteins need just one RRM to 
bind to their target nucleic acids, other proteins require two or more RRMs to bind to the RNA.   
Using two or more RRMs, the protein may expand the RNA binding surface to recognize a 
longer stretch of nucleic acid.  Most of the structures solved to date show that RRMs bind to a 
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stretch of consecutive nucleotides (8-10 nucleotides).  However the NMR structure of 
polypyrimidine tract binding protein (PTB) bound to the polypyrimidine tract of c-src and 
biochemical studies revealed how RRMs may recognize two separated stretches of nucleotides.37  
RRM3 and RRM4 of PTB are tightly bound to each other via their α helices resulting in an anti-
parallel orientation of their bound sequences of RNA (Figure 1.6a).  The two bound sequences 
can be separated by more than 15 nucleotides, which form a RNA loop.37,38  PTB may bind to 
separate polypyrimidine tracts within a pre-mRNA and loop out the exon or the branch point to 
repress splicing of the mRNA.  U2AF is also thought to bind to two separated polypyrimidine 
tracts using two RRMs and the flexible interdomain linker.39  Most proteins that contain multiple 
RRMs have a flexible linker which often plays an essential role in RNA recognition.  The 
association of multiple RRMs with flexible interdomain linkers provides a range of possible 
conformations (Figure 1.6).   The two RRMs of PTB are bound back-to-back so that the RNA 
binding surfaces are facing the opposite direction (Figure 1.6a).37  The two RRMs of 
polyadenylate binding protein (PABP) provide a continuous binding surface (Figure 1.6b).  In 
Sex lethal, HuD, Hrp1, and nucleolin the two RRMs sandwich the RNA (Figure 1.6c and d).18  In 
some cases, the resulting protein conformation induces several intra-RNA interactions that 
contribute to the overall enthalpy of the complex, while in other cases no intra-RNA interactions 
are present.18  These different conformations may contribute to the specificity of the protein.24  
However, it is interesting that three RRM proteins, Sex lethal, HuD and Hrp1 have a very similar 
orientation, while the bound RNAs are different both in sequence and length.24  
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Figure 1.6  Structure of mutiple RRM containing proteins in complex with RNA.  a) RRM3 and 
RRM4 of PTB in complex with RNA.  b) RRM1 and RRM2 of PABP in complex with RNA.  c) 
RRM1 and RRM2 of nucleolin in complex with RNA.  d) RRM1 and RRM2 of HuD in complex 
with RNA.  These structures were generated with the program Chimera.16 
 
 1.2.5 RRM-RRM interactions  
 Both intramolecular RRM-RRM and intermolecular RRM-RRM interactions have been 
observed.  RRMs within a protein may interact to form RNA binding surfaces.  This is shown in 
PTB, as described in section 1.2.4, and Sex lethal.  In the case of Sex lethal, the interaction 
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between the two RRMs clamp the RNA in a cleft formed between the two RRMs.  The RNA 
binding is thought to induce the RRM-RRM interactions.  The structure and the specific 
interactions that form in the complex will be discussed in section 1.4.2.  RRM-RRM interactions 
have also been found in a homodimer-ssDNA complex.  Two FIR proteins that are bound to the 
ssDNA are dimerized using RRM1 and RRM2 of each protein.  While RRM1 recognizes the 
DNA, RRM2 participates in protein-protein contacts.40  It is interesting that RRMs can interact 
with RRMs via both the RNA binding surface and the non-RNA binding surface.  The RRM of 
SRSF1, an alternative splicing regulator, interacts with the RRM of U1-70K using the opposite 
side of the RNA binding surface.19  In contrast, two proteins–Prp24 and Nup35–found in S. 
cerevisiae form RRM-RRM interaction with the RNA binding surface.  In Prp24, a splicing 
factor that binds to U6 snRNA, RRM1 and RRM2 interact with each other.  It is not clear how 
this protein binds to its target RNA since both of the canonical RNA binding surface is occupied 
by RRM-RRM interaction.24  Nup35 protein, which interacts with the nulcear envelope, forms a 
homodimer using the β-sheet surface that contains atypical RNP sequences.   
 
1.3 U1A protein 
 The U1 snRNP specific polypeptide A (U1A) is a component of U1 snRNP and binds to 
the stem loop 2 (SL2) of U1 snRNA.41  It also binds to the polyadenylation inhibition element 
(PIE) of its own pre-mRNA to regulate its expression.42  U1A contains two RRMs, yet only the 
N-terminal RRM interacts specifically with SL2 RNA and PIE RNA.42-44  The crystal structure 
of the N-terminal RRM of U1A in complex with the SL2 RNA was the first solved structure of 
an RRM in complex with RNA.26  Thus U1A-SL2 complex has been extensively used as a model 
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system for studying the biochemical and thermodynamic properties of RRM-RNA 
interactions.45-54 
 
1.3.1 Function of U1A protein 
1.3.1.1 U1A in splicing 
 U1A was first identified as a component of U1 snRNP, which interacts with U2, U4, U5 
and U6 snRNP to form the major (U2-type) spliceosome (Figure 1.7a).  U1 snRNP recognizes 
the 5' splice site and interacts with U2 snRNP.  U1 snRNP consists of seven Sm proteins and 
U1snRNP specific U1-70k, U1A and U1C.  U1C is crucial for the splicing activity of the 
spliceosome.55  U1C aids the U1 snRNA to base pair with the 5' splice site.56  However the 
function of U1-70k and U1A in splicing remain unclear.57  In fact, in vitro splicing was not 
affected by the depletion of U1A55 or the deletion of the stem loop 2 of U1 snRNA.56  Recently, 
Shao et al. have reported that U1A is involved in the communication of U1 snRNP and U2 
snRNP in fission yeast Schizosaccharomyces pombe.  U1A binds to Rsd1, which interacts with 
Prp5.  Prp5 then contacts SF3b of U2 snRNP (Figure 1.7c).58  More biochemical studies are 
required to understand the exact role of U1A during spliceosome assembly and why in vitro 
splicing is not affected by the depletion of U1A or the deletion of the stem loop 2 of U1 snRNA. 
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Figure 1.7  U1A in the spliceosome.  a) Schematic representation of spliceosome. Pre-mRNA 
splicing takes place within the spliceosome, which is composed of four snRNPs (U1, U2, U4/U6, 
and U5).  b) Schematic representation of U1snRNP.  U1snRNP binds to the 5' splice site of the 
target pre-mRNA.  U1A binds to stem loop 2 of U1snRNA.59  c) Protein interaction network of 
U1snRNP-U2snRNP communication during pre-spliceosome assembly.  U1A protein binds to 
SR-like protein, Rsd1. Prp5 binds to Rsd1 and SF3b to connect U1snRNP and U2snRNP.58  
 
1.3.1.2 Autoregulation of its own pre-mRNA 
 In higher eukaryotes, formation of the 3' end of most mRNAs is accomplished by 
endonucleolytic cleavage of the pre-mRNA followed by polyadenylation.60  U1A regulates its 
own production by inhibiting the polyadenylation of U1A pre-mRNA.42,61,62 Two U1A proteins 
cooperatively bind to the polyadenylation inhibition element (PIE) in the 3'-untranslated region 
of its own pre-mRNA.63  Binding of the two U1A proteins to the PIE RNA enables the U1A 
protein to form a surface that interacts with the enzyme responsible for the synthesis of the 
poly(A) tail, poly(A) polymerase (PAP), and inhibits its activity.63-65  The U1A-PIE trimolecular 
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complex does not block the binding of CPSF nor the cleavage reaction, indicating the specificity 
of the inhibition mechanism for the polyadenylation step.66  Without polyadenylation, U1A pre-
mRNA cannot form a mature 3' end therefore is degraded.   
 
1.3.1.3 Regulation of polyadenylation of other pre-mRNAs 
 U1A also controls the polyadenylation of other pre-mRNAs, including pre-mRNAs of 
IgM heavy-chain.67-70 Immunoglobins can occur in two forms, a soluble form that is secreted 
from the cell and a membrane-bound form that is attached to the surface of a B cell.  U1A 
promotes the expression of the membrane-bound form of IgM heavy chain by preventing the 
polyadenylation at the secretory poly(A) site (Figure 1.8a).  U1A binds to sequences 
(A(U/G)GCN1-3C) that resemble the consensus U1A binding site, upstream and downstream of 
the poly(A) site.  U1As that are bound to the three U1A binding motifs upstream of poly(A) 
secretory site, inhibit the polyadenylation using the same mechanism as the autoregulation 
process.67,68  Whereas, U1As that are bound to the two U1A binding motifs downstream of the 
poly(A) site, occlude the binding of cleavage stimulatory factor (CstF) to the downstream GU-
rich motifs and inhibit the formation of the cleavage/polyadenylation complex.69  The N-terminal 
RRM of U1A binds to these novel sites, but with a 10-fold lower affinity than SL2 of U1 snRNA.  
It is suggested that this lower binding affinity is particularly suited to a regulatory role of U1A at 
this poly(A) site, which is fine-tuned by competing weak interactions.67 During B cell 
differentiation the expression of the secretory form of IgM increases.  Investigation of the U1A 
expression level revealed that the lower U1A availability is responsible for changes in its 
inhibitory effect at the secretory IgM poly(A) site.70  Another experiment has shown that the 
level of the U1 snRNP associated U1A decreases upon B-cell stimulation.71  Therefore U1 
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snRNP may be the functional unit for the regulation of IgM polyadenylation.  Expression of 
secretory poly(A) site of other immunoglobins may also be regulated by U1A as implied by 
sequence anaylsis.67  
 
 
Figure 1.8  Regulation of polyadenylation by U1A.  a) Polyadenylation of IgM pre-mRNA.  
U1A binds to five U1A binding motifs and inhibits polyadenylation of secretory poly(A) site.67  
b) Polyadenylation of COX-2 pre-mRNA.  A multi-protein complex including U1A directs the 
use of proximal poly(A) site.72 
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 Regulation of polyadenylation by U1A may be accomplished by forming different multi-
protein complexes.  At least in two cases, U1A has been found to form multi-protein complexes 
independent of U1 snRNP.  It is estimated that about 3% of U1A proteins in the cell are not 
associated with U1 snRNP.73 Polyadenylation of Simian virus 40 (SV40)73-75 and 
Cyclooxygenase-2 (COX-2)72,76 pre-mRNAs is regulated by U1A and other proteins that interact 
with U1A.  In the case of COX-2, two polyadenylation signals (PASs) are present in the 3' UTR; 
proximal and distal polyadenylation signals.76  A protein complex that consists of U1A, p54nrb, 
PSF and PTB binds to the cis-acting upstream sequence elements (USEs) upstream of proximal 
polyadenylation signal and promotes the usage of the proximal polyadenylation signal (Figure 
1.8b).72  The interactions of these proteins were not affected by the presence of RNase.  
Therefore the complex formation is not mediated by an RNA.72,75  A detailed mechanism of how 
this complex induces the polyadenylation at the proximal polyadenylation site is yet to be 
determined.  
 
1.3.2 Structure of U1A protein and U1A-RNA complexes 
 The human U1A is a 32 kDa protein comprised of two RRMs joined by a flexible linker 
rich in proline and lysine.  Among the two RRMs only the N-terminal RRM (RRM1) interacts 
specifically with SL2 RNA of U1 snRNA and PIE RNA of its own pre-mRNA.  No RNAs have 
been shown to bind to the C-terminal RRM (RRM2).43,77  The structures of the free RRM1, free 
RRM2, RRM1-SL2 RNA complex, and RRM1-PIE RNA have been solved by X-ray 
crystallography and NMR.26,28,63   
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1.3.2.1 U1A-SL2 RNA complex 
 N-terminal RRM of U1A recognizes the single stranded element AUUGCAC in the stem 
loop 2 of U1 snRNA and contacts the GC base pair that closes the stem loop.  U1A binds weakly 
to a RNA that has the same consensus sequence but does not form a stem loop.  The three 
residues (UCC) that are in the loop but do not contact the RNA are flexible and can be 
randomized or replaced by a polyethylene glycol spacer.78,79 
 RRM1 of U1A follows the basic binding mode utilizing the conserved aromatic residues 
in β1 and β3.  Residues that correspond to position 2 of RNP2 and position 5 of RNP1 are Tyr13 
and Phe56, which form stacking interactions with C10 and A11, respectively.  Position 3 of 
RNP1 is a glutamine that forms a stacking interaction with G9 of the RNA.  Glu54 also forms 
hydrogen bonds with the hydroxyl group of Tyr13 positioning it to form the stacking interaction 
with C10.   
 Loop 1 and loop 3 actively participate in recognition of the RNA.  Asn16, Leu17, Glu19 
in loop 1 forms direct or water mediated hydrogen bonds with the RNA.  Loop 3 (Ser46-Arg52) 
is flexible in the free protein but becomes fixed in the complex.  The loop protudes into the RNA 
loop presenting the bases of the RNA to the β-strands of the protein.  Arg52 plays a crucial role 
in binding.  Mutation of Arg52 to glutamine abolishes RNA binding.  Arg52 not only contacts 
two nucleotides (A6 and G16; Figure 1.5a) but also forms a hydrogen bond with two residues in 
loop 3 (Arg47 and Ser48) defining the conformation of loop 3.  
 Helix C is in a closed form contacting the β-surface of the RRM1 in the free protein and 
is moved away from the β-surface exposing the β-surface for RNA binding.  When the protein is 
bound to the RNA, residues in helix C directly contact the RNA by forming direct or water 
mediated hydrogen bonds (Figure 1.9c). 
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Figure 1.9  a) Structure of U1A-SL2 RNA.  b) Sequences of SL2 RNA.  c) Structure alignment 
of free U1A (blue) and RNA bound U1A (orange).  d) Primary sequence of N-terminal RRM of 
U1A protein.  These structures were generated with the program Chimera.16 
 
1.3.2.2 U1A-PIE RNA complex 
 The 3' untranslated region of U1A pre-mRNA folds into a conserved secondary structure 
with two internal loops; one loop contains the consensus sequence (AUUGCAC) and the other 
its variant (AUUGUAC) (Figure 1.10a).61  Two U1A proteins bind cooperatively to two internal 
loops and form a trimolecular complex.  This trimolecular complex was proposed using a 
modeling program80 and verified by an NMR structure with a similar RNA sequence (Figure 
1.10b).63  Although the structure of the PIE RNA is quite different from the SL2 RNA, the U1A-
PIE complex is formed using the same sequence-specific interactions between the RNA and the 
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protein with slight variation in the helix C-RNA interface.  The cooperativity of the two U1A 
molecules is directed by protein-protein interactions and not by protein-induced changes in the 
RNA.    
  
 
Figure 1.10  a) Sequence of PIE RNA and RNA used in the NMR structure. Sequences that 
directly contact U1A are highlighted in red.  b) Structure of the U1A-PIE complex. (pdb: 1DZ5)  
c) Close-up view of helix C-helix C interaction.  These structures were generated with the 
program Chimera.16 
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 The protein-protein interaction is mediated by helix C.  Helix C is amphiphatic, with 
hydrophilic residues (Asp92, Lys96, Lys98) pointing to the RNA or exposed to the solvent and 
hydrophobic residues (Met97, Thr100, Val102) participating in protein-protein interactions.  
Met97 is at the core of the helix C interaction, packed against Ile93 and contacting Gly99, 
Thr100 and the other Met97 (Figure 1.10c).  Due to these interactions helix C becomes more 
rigid.30  The sequence following helix C contains the PAP binding site, which spans residues 
103-115.64  This sequence contains conserved basic and acidic amino acids and mutations of 
some of the basic amino acids reduce inhibition of PAP.65  Based on the NMR structure, the PAP 
binding region may be formed by an extension of helix C.   
 
1.4 Sex lethal protein 
 The Sex lethal protein is a master switch for determining the sex of Drosophila 
Melanogaster. Produced only in female flies, Sex lethal directs all aspects of female 
development and prevents the activation of the male-specific dosage compensation system.  In 
males, Sxl is OFF, resulting in male development and activation of X chromosome dosage 
compensation.  Sex lethal regulates alternative splicing and translation of pre-mRNAs that are 
involved in sex development and dosage compensation.  These post-transcriptional regulation 
processes are accomplished by the protein's ability to specifically bind to its target RNAs.  Sex 
lethal contains two RRMs and, unlike U1A, it requires both RRMs to bind RNA. 
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1.4.1 Sex lethal and sex determination of Drosophila Melanogaster 
1.4.1.1 Expression of Sex lethal: Activation and maintenance 
 Sxl contains two promoters: establishment (Pe) and maintenance (Pm).81,82  The 
establishment promoter is temporarily available during early embryogenesis and is permanently 
shut down at the cellular blastoderm stage.82,83  The use of establishment promoter depends on 
the number of X chromosomes, which leads to an all-or-none response of Sxl.83,84  Four X-
encoded proteins, collectively called X-linked signal elements (XSE), serve as the primary 
determinants of X chromosome dose.82  Three of the XSE proteins–SisA, Scute and Runt–are 
transcription factors that stimulate the transcription of SxlPe.85  Another XSE protein, Unpaired 
activates the maternally supplied Stat92E transcription factor, which in turn reinforces the 
activation of SxlPe.86-88  In female flies (XX), the concentrations of these four XSE proteins 
reach a certain threshold level to activate the transcription of SxlPe (Figure 1.11a).83  Whereas in 
males (XY), XSE proteins never exceed threshold levels and Pe remains inactive (Figure 1.11b).  
Once the X chromosome dose has been assessed, the establishment promoter is inactivated and 
Sxl is primarily transcribed by the maintenance promoter.82  The transcript from the maintenance 
promoter contains a male-specific exon, which includes multiple premature stop codons.  In 
females, Sex lethal forces this exon to be skipped, therefore producing the full-length functional 
protein (Figure 1.11c).  In males, absence of Sex lethal leads to the inclusion of the male-specific 
exon, resulting in truncated non-functional proteins (Figure 1.11d).  Thus, the autoregulatory 
splicing of Sex lethal converts the transient X chromosome dose signal into long-term cellular 
memory.   
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Figure 1.11 Expression of Sex lethal in Drosophila Melanogaster.  a) Early expression of Sex 
lethal in female flies.  b) In male flies, the establishment promoter is not used and results in no 
transcription.  c) Once the early Sex lethal is expressed, it regulates alternative splicing of its 
own pre-mRNA resulting in the translation of Sex lethal.  d) In males, the absence of Sex lethal 
results in a transcript that includes multiple stop codons in the middle of the transcript, which is 
transcribed into a non-functional truncated Sex lethal. 
 
 Two Sex lethal binding sites have been identified in its own pre-mRNA.  One is >200 
nucleotides downstream and the other is >200 nucleotides upstream of the male-specific 
exon.89,90  Sex lethal proteins bound to these sites are proposed to interact with general splicing 
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factors (U2AF and SPF45) and components of U1 snRNP (SNF and U1-70k) to inhibit their 
function.91  Recent studies have suggested that other proteins may also promote exon skipping 
including Transformer, which is a downstream target of Sex lethal.92	  
 
 
Figure 1.12 Sex determination pathway of D. Melanogaster. The X chromosome dose signal 
targets the Sxl gene, establishing the autoregulation of Sxl in embryos. Sxl, tra, msl-2, dsx, and 
fru genes are all differentially spliced in males and females. Sex lethal protein turns on Sxl itself 
and tra via alternative splicing of the corresponding pre-mRNAs. Transformer then activates 
female-specific splicing of dsx and fru. The absence of Transformer protein in male results in 
male-specific protein variants of dsx and fru that regulate distinct sets of target genes. The 
production of Msl-2 protein is prevented by Sex lethal in female flies. 
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1.4.1.2 Splicing and translational regulation of target genes 
 Sex lethal is at the top of the sex determination pathway, orchestrating sex-specific 
development and behavior by modulating the expression of a set of downstream genes (Figure 
1.12).82,93  Sex lethal has been found to regulate the expression of at least two target genes–
transformer (tra) and male-specific lethal-2 (msl-2)–aside from Sxl itself.82   
 Tra is the primary effector through which Sxl controls sexual differentiation.82,94  
Transformer is an RNA binding protein that activates female-specific splicing of doublesex (dsx) 
and fruitless (fru) genes.95  Sex lethal protein controls alternative splicing of tra pre-mRNA by 
binding to the polypyrimidine tract associated with the non-sex specific splice site and diverting 
U2AF, a general splicing factor to the downstream polypyrimidine tract.96  Thus U2AF recruits 
the splicing machinery to the female-specific splice site (Figure 1.13).  Use of the proximal 3’ 
splice site introduces a stop codon in the open reading frame leading to the translation of a non-
functional protein while the use of distal 3’ splice site results in a functional Transformer protein.  
In females, approximately half of the tra pre-mRNA is spliced at the downstream splice site to 
produce Transformer protein.97,98  
 In males, X chromosome dosage compensation complex is formed, which increases the 
transcriptional output of the X chromosome.  Msl-2 is a component of this dosage compensation 
complex required for its function.  In females, the expression of Msl-2 is repressed by Sex lethal 
thereby inhibiting the formation of the dosage compensation complex.  Sex lethal not only 
regulates the splicing of msl-2 in the nucleus but also inhibits the translation of the transcript in 
the cytoplasm.  Msl-2 RNA contains multiple Sex lethal binding sites at both the 5' and 3' 
untranslated regions (UTR).  At the 5' UTR, Sex lethal binds to both the 5' splice site and the 3' 
splice site of the first intron and prevents the splicing of this intron.  At the 5' splice site, Sex 
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lethal displaces Rox8, which enhances the use of the weak 5' splice site.  At the 3' splice site, Sex 
lethal blocks the binding of U2AF as in tra RNA (Figure 1.13).  Interestingly, the retention of 
this intron does not have an effect on the final protein product since it is not in the open reading 
frame.99,100  Instead, Sex lethal proteins bound to the intron are used to suppress the translation of 
msl-2 by inhibiting the scanning of the 43S ribosome subunit.  In addition to this mechanism, 
Sex lethal proteins bound at the 3' UTR block the binding of 43S complex to the 5' end of the 
mRNA.  This is achieved by recruiting a co-repressor, Upstream of N-ras (UNR), which in turn 
binds to PABP (Figure 1.13).101-104 However the exact mechanism of 43S complex inhibition 
needs further investigation. 
 
 
Figure 1.13  Splicing regulation by Sex lethal.  a) tra RNA.  b) msl-2 RNA.94  
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 The exact number of target genes of Sex lethal is not known.  Recent bioinformatic 
approaches105 and biochemical studies106,107 have identified a few more plausible targets.  For 
example, Sex lethal down-regulates Notch protein, which controls the bristle number on the adult 
cuticle.107  Notch mRNA contains several Sex lethal binding sites in its 5' and 3' UTRs and Sex 
lethal is capable of binding Notch mRNA.  The number and distribution of the Sex lethal binding 
sites are similar to that of msl-2.  However whether the mechanism of translational repression is 
the same as that of msl-2 is not known.107  
 
1.4.2 Structure of Sex lethal-tra RNA complex 
 Sex lethal is a 354 amino-acid protein that binds to polypyrimidine tracts in mRNAs 
using two RNA recognition motifs.  Unlike U1A, Sex lethal requires both RRMs for it to bind to 
the target sequence.  Like many of the RRM proteins, Sex lethal binds to unstructured single 
stranded RNAs.  Biochemical analysis using SELEX revealed that Sex lethal binds to a 
consensus sequence of UUUUGUU(G/U)U(G/U)UUU(G/U)UU.108  Based on this consensus 
sequence, genome analysis identified more than 10,000 potential Sex lethal binding sites in 
Drosophila genome.105   
 Crystal and NMR structures of Sex lethal free and bound to the polypyrimidine tract 
(GUUGUUUUUUUU) of tra RNA have been solved.36  The overall structure of the complex is 
shown in Figure 1.14a.  The two RRMs have their β-sheet surfaces facing each other forming a 
V-shaped cleft.  Sex lethal recognizes nine nucleotides (U3-U11) continuously.  The cleft is 
strongly electropositive and binds to six nucleotides in the 3' end (U6-U11). RRM2 contacts 
three nucleotides (U3-G4-U5) close to the 5' end.  The bound RNA has a turn in the middle, 
which is characterized by an intramolecular stacking interaction between U7 and U8.  The main 
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difference between the structure of the free protein and the complex comes from the interdomain 
linker.  According to NMR studies and crystal structure of the free protein, the linker between 
the two RRMs is unstructured and flexible without the RNA.109,110  However upon RNA 
recognition it forms a rigid 310 helix and forms hydrogen bonds with RRM2.  In addition to the 
conformational change of the linker, two electrostatic contacts form between the two RRMs that 
are not observed in the free protein.  The side chain of Lys197 contacts the main chain carbonyl 
group of Val238 and the hydroxyl group of Tyr131 contacts the side chain of Glu239 (Figure 
1.14b). 
 The conserved RNP sequences of RRM1 and RRM2 participate in stacking interaction 
with the RNA bases (Figure 1.14c).  Residues of RNP1 position 5 in both RRMs are 
phenylalanines that form stacking interactions with U11 and U5 respectively.  In RRM2, the 
third residue of RNP1 is Val254 and the second residue in RNP2 is Tyr214, which each form 
stacking interactions with U3 and G4.  The corresponding residues in RRM1 do not form 
stacking interactions with any bases.  Instead, position 4 and 5 of RNP2 in RRM1–Asn130 and 
Tyr131–forms stacking interaction with U9 and U6.  Overall, six stacking interactions, which are 
mediated by residues in the two RNP sequences, play a significant role in the binding affinity of 
the protein-RNA complex.  Similar to most RRM proteins, these residues do not contribute to the 
specificity of the protein. 
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Figure 1.14  Structure of Sex lethal-tra RNA complex.  a) Overall structure of the complex.  α 
helices are in blue, β strands are in light blue, 310 helix in the interdomain linker is in purple and 
the RNA backbone is in yellow.  b) RRM-RRM interaction.  c) Stacking interactions formed 
between Sex lethal and RNA via residues in the RNP sequences.  These structures were 
generated with the program Chimera.16	  
 
 Residues in the loop regions as well as β strands are responsible for the specific 
recognition of the tra RNA.  They form hydrogen bonds or have electrostatic interactions with 
the RNA bases (Table 1.2).  All nine nucleotides (UGUUUUUUUU) are specifically recognized 
by the Sex lethal.  These specific interactions explain the mechanism by which uridine-rich 
sequences with one or more cytidine residues bind weakly to the Sex lethal.33,111  However, 
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substitution of uracil with guanine is tolerated in some positions, presumably because uracil and 
guanine have similar functional displayed along the edge of the base.33   
 
Table 1.2  Salt bridges formed between Sex lethal and tra RNA bases. 
 
 
 Sex lethal does not bind to DNA or an RNA containing deoxyuridines.33,34  Consistent 
with these binding studies, six of the nine 2'-OH groups are in contact with Sex lethal residues.  
Moreover, tra RNA contains intramolecular hydrogen bonds between the 2'-OH and phosphate 
groups in the complex.  These contacts form the kink in the middle of the RNA that allows the 
protein to interact with RNA bases.    
 
1.5 Summary 
 RNA binding proteins play an essential role in all steps of gene expression and gene 
regulation.  RNA binding proteins are built from a small number of RNA-binding domains to 
create a diverse set of RNA binding proteins many of which remain to be discovered and 
characterized.  The RNA recognition motif is an abundant and diverse RNA binding domain 
found in all organisms.  Biochemical studies and structural analysis of RRM-containing proteins 
have shown that this small domain is extremely diverse in terms of both function and structure.     
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   The U1A protein is not only found as a component of the U1 snRNP but also in a 
distinct complex that regulates polyadenylation of several pre-mRNAs.  Although U1A contains 
two RRMs, only the N-terminal RRM interacts specifically to bind RNA.  Extensive structural 
and biochemical studies have been performed on the U1A-SL2 RNA complex making it an ideal 
model system to study RRM-RNA interactions.  The Sex lethal protein is an alternative splicing 
regulator that determines the sex of Drosophila Melanogaster.  Sex lethal binds to unstructured 
single-stranded RNA using both RRMs.  In the following two chapters, Sex lethal-tra RNA and 
U1A-SL2 RNA complexes are used as a model system for the identification of small molecule 
inhibitors of RRM-RNA interactions and to understand the kinetics of RRM-RNA complex 
dissociation. 
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CHAPTER 2 
Small Molecule Inhibitors of RNA Recognition Motif-RNA Interactions 
 
2.1 Introduction  
 RNA-binding proteins play a key role in transcription and post-transcriptional events, 
including alternative splicing, transport, stability, localization and translation.1-3  Moreover 
RNA-binding proteins bind to small interference RNAs and microRNAs, which regulate 
transcription, RNA stability and translation.3,4  Therefore, small molecule inhibitors of 
complexes formed between RNA-binding protein and RNA would be valuable tools to study 
these post-transcriptional processes and could be used to regulate gene expression at the post-
transcriptional level.  This chapter will describe the identification of three unrelated small 
molecules that destabilize two different RRM-RNA complexes by binding to the protein.   
 
2.1.1 Small molecule inhibitors of protein-RNA interaction 
 Small molecule inhibitors have been mostly developed to target disease-related proteins 
or nucleic acids for the obvious need of medicine.5,6  For the past two decades small molecules 
were also recognized as excellent probes to study the function of proteins and cellular processes 
since they provide rapid, reversible and dose-dependent control over protein functions.  In the 
field of chemical genetics, small molecules serve as a complementary tool to classic genetics and 
siRNA to understand the function of a specific protein.7-9  Given the importance of protein-RNA 
interactions in a wide range of cellular processes, it is necessary to discover small molecule 
inhibitors of protein-RNA interactions.   
 Small molecules that inhibit protein-RNA interactions can be divided into two classes: 
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RNA binders and protein binders.  Many small molecules that bind to different target RNAs and 
inhibit the interactions of protein-RNA complexes have been reported.10  The most extensively 
studied systems are Tat protein-TAR (trans-activating response element) and Rev-RRE (Rev 
response element) from the human immunodeficiency virus type 1 (HIV-1).  Tat protein 
facilitates the transcription of the HIV-1 genome by binding to TAR, which is a bulged RNA 
hairpin loop present in the 5' end of all mRNAs.  In a complementary step, the Rev protein 
regulates splicing and exports the transcribed RNAs from the nucleus of the host cell to the 
cytoplasm.  The Rev protein binds with high affinity and specificity to a stem loop within the 
RRE and promotes oligomerization of Rev proteins.  This process triggers the "late" gene 
expression.  Therefore, inhibition of the Tat-TAR and the Rev-RRE complexes would have a 
strong negative effect on the HIV life cycle.  Since both TAR and RRE present unique structural 
features that can be targeted with small molecules, many researchers focused on finding 
compounds that bind to the RNA.  As a result, numerous small molecules including intercalators, 
intercalator-arginine conjugates, guanidinylated compounds, aminoquinolones, diphenylfurans, 
aminoglycosides, acridines were found to inhibit these complexes.10   
 In some cases it is necessary to disrupt the protein-RNA interaction by binding to the 
RNA and not the protein.  Myotonic dystrophy is a genetic disease caused by a trinucleotide 
repeat expansion.11  In type I mytonic dystrophy (DM1), there is an aberrant expansion of CTG 
repeats (from 80 to >2,000 repeats) in the 3' untranslated region of the DMPK gene.12  When the 
expanded sequence is transcribed into the RNA, it sequesters a critical splicing regulatory protein, 
muscleblind-like (MBNL) protein, which results in missplicing of several target pre-mRNAs.  
For therapeutic agents, compounds that bind the RNA and do not bind to the protein should be 
identified.  Several compounds that specifically bind to the CUG repeat of mRNA have been 
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identified and some of them have been shown to reverse the splicing defects.13-16 
 Examples of small molecules that bind to the protein and inhibit protein-RNA 
interactions are rare.  Hamy and co-workers have reported a disulfonated stilbene compound that 
inhibits the Tat-TAR complex.17  They proposed this compound binds to the Tat protein based on 
the fact that it did not bind to the RNA in any of the traditional RNA binding experiments and 
pre-incubation of the compound with Tat increased the potency.  The compound was able to 
inhibit Tat transactivation in cells and viral replication.   In another example, a computer based 
screen identified compounds that disrupt the binding of double-stranded (ds) RNA to toll-like 
receptor 3 (TLR3).18  A compound library was screened against the dsRNA-binding domain of 
TLR3.  Experimental analysis confirmed the activity of the hits obtained from the computer 
screen, however, whether the compounds bind to the protein or the RNA was not experimentally 
shown.  Small molecules that target RNA binding proteins may be used to probe the specific 
function or provide information of the RNA binding mechanism.  Moreover if the compound can 
specifically target one domain in a multi-domain RNA binding protein, it may give insight into 
the role of that specific domain within the protein. 
  
2.1.2 Small molecule inhibitors of RRM-RNA complexes 
 To date, there are only a handful of compounds that inhibit RRM-RNA interactions.  An 
aminoacridine derivative was found to inhibit the complex formed between U1A and stem loop 2 
RNA (SL2). 19   Fluorescence experiments showed that the compound binds to the RNA for its 
inhibitory activity.  Interaction of the HuR protein with the AU rich element (ARE) was targeted 
by several groups, since HuR has been implicated in various types of cancers.20-22	   Meisner and 
coworkers have identified several small molecule inhibitors of HuR-ARE complex by screening 
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microbial and plant extracts.20  To confirm the compound binding site, they first hypothesized 
several different binding models based on whether the compound binds to the HuR monomer, 
dimer or the RNA.  Then they calculated the binding curves of each model using a mathematical 
program and compared the curves with the experimental data.  Based on this analysis they 
suggested that these compounds bind to the protein to prevent the complex formation.20  Both 
stem loop 2 of U1 snRNA and ARE form stable secondary structures.  There are no inhibitors of 
complexes formed between RRMs and unstructured RNAs, although many RRMs bind to 
unstructured RNA targets.  The flexibility of RNA and the typically broad interaction surface 
between RRMs and RNAs pose a significant challenge to find small molecules that inhibit the 
interactions between RRM and unstructured, single-stranded RNA complexes.23 
 To add to the small number of RRM-RNA inhibitors and to investigate the possibility of 
inhibiting a complex between a protein and an unstructured single-stranded RNA, we performed 
a high throughput screen using the Sex lethal-tra RNA complex as a model system.  We 
identified three micromolar inhibitors of the Sex lethal-tra RNA complex, which bind to Sex 
lethal and destabilize the complex.  A selectivity assay with the U1A-SL2 complex revealed that 
one of the compounds is a potent and selective inhibitor of U1A-SL2 interactions.  Together, we 
demonstrate that challenging targets such as RRM and single-stranded RNA interactions may be 
disrupted with small molecules that bind to the protein. 
 
2.2 Results and Discussion 
2.2.1 Selection of Protein-RNA constructs   
 To identify small molecule inhibitors of RRM-RNA interactions, we developed a 
fluorescence anisotropy screen to monitor the increase or decrease in Sex lethal-RNA binding 
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upon addition of a small molecule.  Sex lethal protein has been structurally characterized by X-
ray crystallography bound to a portion of the tra pre-mRNA (Figures 2.1a and c),24 and its 
binding affinity for the tra pre-mRNA has been studied extensively.25-27  Therefore, we used the 
Sex lethal-tra RNA complex as a model system for identifying small molecule inhibitors of Sex 
lethal-RNA interactions. 
 
Figure 2.1 Diagram of RRM-RNA complexes from the X-ray cocrystal structures, and RNA 
sequences used in this study.  a)  Sex lethal-tra RNA (pdb: 1B7F).24  b) U1A protein-SL2 RNA 
complex (pdb: 1URN).28  c) Polypyrimidine tract of tra RNA. The sequence shown in the 
structure is underlined in black.  Nucleotides that have direct contact with the protein are 
indicated with blue lines above the sequence.  d) Stem loop 2 of U1 snRNA.  The 7 residues of 
the loop that have close contact with the protein are indicated with a blue line above the 
sequence.  The structures were generated with the program Chimera.29 
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2.2.2 Fluorescence anisotropy binding assay.  
 For the high-throughput screen, a fluorescence anisotropy binding assay with a labeled 
RNA target was employed.  To maximize the magnitude of the fluorescence anisotropy signal 
increase upon protein binding, we used a short 11mer tra RNA (U8~C18, Figure 1b) with a 
fluorescein label at the 5' end.  Titration of Sex lethal protein into solutions of tra RNA resulted 
in a reproducible binding curve showing increase in fluorescence anisotropy upon complex 
formation (Figure 2.2).  The calculated Kd was comparable to that obtained from electrophoretic 
mobility shift assays (Figure 2.7b). 
 
 
Figure 2.2 Fluorescence anisotropy based assay for Sex lethal-tra RNA binding.  Increasing 
concentration of Sex lethal protein increases the fluorescence anisotropy indicating Sex lethal 
protein-tra RNA complex formation.  Kd value was calculated to be 7.5 ± 1.5 nM.  The data 
represent average of 3 independent measurements. 
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Figure 2.3 Identification of inhibitors of the Sex lethal-tra RNA complex. a) Fluorescence 
anisotropy assay of 28 initial hits in the presence of 0.1% Triton X-100.  100 µM of each 
compound was incubated for 1h with 0.5 µM Sex lethal and 3 nM tra RNA in HEPES buffer.   C 
is the DMSO control, RO is RNA only and CR is Congo red, a known aggregator.  Error bars 
represent SD from 3 independent experiments.  b) Six compounds (5, 6, 7, 8, 22 and 28) selected 
from the fluorescence anisotropy assay were subjected to an electrophoretic mobility shift assay 
in the presence of 0.5% Triton X-100 and 0.2 mg/mL BSA.  100 µM of each compound was 
incubated for 2h with 0.1 µM protein and 400 pM RNA.  C is the DMSO control and RO is RNA 
only. Representative gel of three independent experiments is shown. c) Structure of compounds 5, 
7, and 8. 
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2.2.3 Compound screening.  
 We chose to utilize the Chembridge library (32,000 compounds) and NCI library (10,560 
compounds) for high throughput screening because they contain compounds with a high degree 
of molecular structural diversity and compounds can be obtained from the NCI or purchased for 
experimental evaluation.  Screening was carried out in 384 well plates at the high-throughput 
screening facility at University of Illinois.  Compounds to be evaluated were added to a solution 
of the Sex lethal-tra RNA complex and the decrease in anisotropy was monitored to identify 
inhibitors. DMSO alone was used as the negative control, and because there is no known 
compound that inhibits the Sex lethal protein-RNA complex, labeled RNA alone was used as the 
positive control in each plate.  These experiments identified 28 compounds with more than 40% 
inhibitory activity, which were selected as primary hits. Compounds identified by high-
throughput screening are often false positives due to their ability to form aggregates in buffered-
solutions.30,31  Small molecule aggregates can isolate the protein from the RNA, which reduces 
the fluorescence anisotropy signal.  It has been shown that 0.1% of Triton X-100 can efficiently 
minimize small molecule aggregation.31  Therefore the primary hits were screened again in the 
presence of 0.1% Triton X-100 (Figure 2.3a).  Six compounds that had lower anisotropy values 
than the DMSO control were used for further analysis.  
 
2.2.4 Electrophoretic mobility shift assay  
 Because fluorescence anisotropy is a fluorescence-based method, compounds that absorb 
or are fluorescent at the excitation or emission wavelength can also produce false positive 
signals.32  To eliminate these compounds we performed a secondary assay that does not involve a 
fluorescence-based readout, the electrophoretic mobility shift assay (EMSA).  EMSA is based on 
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the observation that the migration of the protein-RNA complex is slower than the unbound 
radiolabeled RNA in a native polyacrylamide gel during electrophoresis.33  The inhibition of the 
Sex lethal-tra RNA complex, was monitored by observing the decrease in the intensity of the 
protein-RNA complex band and the increase in the free RNA band in the gel upon addition of 
the compounds (Figure 2.3b).  In addition to Triton X-100, bovine serum albumin (BSA) was 
found to attenuate compound aggregation when pre-incubated with the compound.34  Therefore, 
the compounds (100 µM) were pre-incubated with 0.2 mg/mL of BSA for 10 minutes followed 
by the addition of the Sex lethal-tra RNA complex.  For the lanes with compounds 6, 22, and 28, 
less than 40% inhibition were observed.  These compounds are thought to be false positives due 
to aggregation or fluorescence of the compounds and were discarded. 
 Three distinct compounds inhibited the Sex lethal-tra RNA complex at high 
concentrations of Triton X-100 and BSA (Figure 2.3b).  Compounds 5, 7, and 8 effectively 
inhibited the pre-formed Sex lethal-tra RNA complex with 62, 93 and 40% inhibition, 
respectively.  The structures of the three hit compounds are shown in Figure 2c.  Compound 5 is 
an arylstibonic acid that has been found to inhibit several DNA binding proteins including bZIP 
transcription factor, poxyvirus type 1 topoisomerase, and human apurinic/apyrimidinic 
endonuclease 1.35-37  Compound 7 is a disulfonated stilbene dye with two catechol moieties. 
Despite its small size, compound 8 was also identified as an inhibitor of the Sex lethal-tra 
complex.  
 
2.2.5 Controlling for Aggregation  
 A few dyes, including Congo red, have been reported to form aggregates and 
promiscuously inhibit enzymes.38  Concerned with the fact that compound 7 is a dye with azo 
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moieties and compound 5 has been identified as an inhibitor of other proteins we evaluated these 
compounds with dynamic light scattering to further explore the possibility of these compounds 
being aggregation-based inhibitors.  Colloid-like large particles formed by small molecules can 
be detected with dynamic light scattering.  There was no evidence that compounds 5 and 8 
formed any particles, even at concentrations of 500 µM.  For compound 7, peaks appeared 
randomly, which were averaged to a small particle size and a high standard deviation (Table 2.1). 
We analyzed the autocorrelation functions of the dynamic light scattering data.30  In comparison 
with the known aggregator Congo red, the autocorrelation function of compound 7 did not show 
a well-defined autocorrelation function.  This suggests that pre-formed aggregates of compound 
7 are not responsible for the observed inhibition of Sex lethal-tra RNA complex (Figure 2.4). 
 
Table 2.1 Dynamic light scattering data of Congo red and three inhibitors.  
 
a Peaks were observed randomly reflected in the high standard deviation. 
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Figure 2.4 Representative autocorrelation functions from dynamic light scattering.  Compound 
aggregation was analyzed by dynamic light scattering.  Formation of particles was monitored 
with 500 µM of each compound in HEPES buffer. 
 
2.2.6 IC50 values.  
 Dose-dependent inhibition of the Sex lethal-tra RNA complex by the selected 
compounds was analyzed using EMSA. The concentration of Sex lethal was adjusted so that 
80% of the radiolabeled tra RNA was bound to the protein. To this solution of pre-formed 
complex, increasing amounts of compounds were added and subjected to electrophoresis (Figure 
2.5a). We found that compound 5, 7, and 8 inhibit the Sex lethal-tra RNA complex dose-
dependently with IC50 values of 22 ± 1 µM, 5 ± 1 µM and 14.4 ± 0.4 µM, respectively (Table 
2.2).  
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Figure 2.5  Representative EMSA gels showing dose-dependent titrations of compounds into 
solutions of the protein-RNA complex (~80% fraction bound).  a) Sex lethal-tra RNA complex. 
Highest concentrations of the compounds were 200 µM.  Compounds were incubated with 0.1 
µM Sex lethal and 400 pM tra RNA in HEPES buffer that contains 0.5 % Triton X-100.  b) 
U1A-SL2 complex. Highest concentrations of the compounds are indicated on top of each gel.  
Compounds were incubated with 5 nM Sex lethal and 50 pM SL2 RNA in Tris buffer that 
contains 0.5 % Triton X-100. 
 
Table 2.2 IC50 values of the three inhibitors against Sex lethal-tra and U1A-SL2 RNA 
complexes. 
 
 
2.2.7 Fluorescence binding assays 
 To understand whether the compounds are binding to the RNA or the protein to achieve 
their inhibitory activity, we used fluorescence spectroscopy.  First, to detect whether the 
compounds bind to the RNA, compounds were titrated into a 100 nM of 5'-fluorescein labeled 
11mer tra RNA solution.  We used a shorter RNA construct so that if the compounds bind to the 
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RNA, the fluorescein is closer to the bound site and more likely to give a signal change. 
Although this experiment cannot conclusively tell us whether the compounds are binding to the 
RNA, if we do observe a signal change we can positively identify compounds that bind to the 
RNA.  However no fluorescein quenching was observed up to concentrations of 127 µM of the 
compounds (Figure 2.6).  The compounds may not be binding to the RNA or they could bind to 
the RNA in a manner that does not quench the fluorescein.  Compound 7 was not subjected to 
the RNA fluorescence experiment due to its large absorption at the excitation wavelength of 
fluorescein. 
 In a separate experiment, we introduced a tryptophan residue into Sex lethal as a 
fluorescence label.  Phe256 is a highly conserved residue and participates in stacking interactions 
with uracil 7 of tra RNA.24  This interaction is important for the binding.39  Assuming the 
compounds would bind to the protein surface where it interacts with RNA to inhibit the protein-
RNA interaction we mutated this residue to a tryptophan to monitor the fluorescence quenching 
of the Trp by the compounds.  There are no other Trp residues in the protein.  Before using the 
Sex lethal (F256W) mutant we confirmed that this phenylalanine to tryptophan mutation does 
not affect the overall structure of the protein by circular dichroism (CD) analysis and that the WT 
and the mutant proteins have comparable Kd values by EMSA (Figure 2.7).  
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Figure 2.6  Fluorescence-binding assays indicating that all three compounds bind to the protein.  
Two independent fluorescence-binding assays were performed using fluorescein labeled RNA 
and Sex lethal (F256W).  Compounds were titrated into a solution of fluorescein labeled RNA or 
Sex lethal (F256W).  Normalized fluorescence intensity of the RNA and the protein is shown in 
the y-axis upon titration of a) compound 5, b) compound 7 or c) compound 8.  d) A control 
experiment with Tryptophan.  Compounds were titrated into a solution of Tryptophan and the 
fluorecence intensity was monitored. 
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Figure 2.7  The Phe256Trp mutation does not affect the overall structure and the binding affinity 
of the protein.  a) Circular dichroism analysis of Sex lethal WT and Sex lethal (F256W).  b) 
Binding curves obtained from electromobility shift assay (EMSA) of Sex lethal WT and Sex 
lethal (F256W). 
 
 Concentrated solutions of compounds in DMSO were titrated into a 2 µM Sex lethal 
solution and the Trp fluorescence was monitored at 355 nm.  The change of the fluorescence 
signal of the mutant protein due to the addition of DMSO was subtracted from that observed 
upon addition of the compounds and the inner filter effect of the compounds were corrected as 
described in the experimental section.  Normalized fluorescence intensity versus compound 
concentration is plotted in Figure 5.  All three compounds quenched the tryptophan fluorescence 
of the protein dose-dependently.  As a control, the fluorescence intensity of a solution of 
tryptophan was measured upon compound titration (Figure 2.6d), and no quenching of the 
tryptophan signal was observed.  This result shows that the compounds do not directly bind to 
the free tryptophan and suggests that the fluorescence quenching observed with the F256W 
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mutant is a result of the compounds binding to the protein.  Binding curves are shown in Figure 
S3.  The apparent Kd of the three compounds bound to Sex lethal was comparable to the Ki 
values calculated from IC50 values (Figure 2.6d).  These results suggest that binding of the 
compounds to the protein prevents Sex lethal-tra RNA complex formation.  
 
2.2.8 Selectivity of the compounds  
 To assess the selectivity of these compounds for the Sex lethal-tra RNA complex, we 
tested their ability to destabilize a different RRM-RNA complex, that of the U1A protein binding 
to SL2 RNA. We used the N-terminal RRM of U1A protein and stem loop 2 RNA to test the 
inhibitory activity of the compounds by EMSA (Figure 2.8b). For a fair comparison of the 
compounds' activity against Sex lethal and U1A, we adjusted the amount of U1A so that 80% of 
SL2 RNA is bound to the U1A protein. Interestingly, we observed complete inhibition of the 
U1A-SL2 complex at low micromolar concentration with compound 8 and high nanomolar 
concentration with compound 7, whereas compound 5 did not completely inhibit complex 
formation even at 1.6 mM. Compound 7 has 10-fold higher potency against the U1A-SL2 RNA 
complex than the Sex lethal-tra RNA complex. Compound 8 is approximately a 2-fold stronger 
inhibitor of the U1A-SL2 complex compared to the Sex lethal-tra- RNA complex.  Thus, we 
have identified compound 5 as a selective inhibitor of the Sex lethal-tra complex and compound 
7 as a selective inhibitor of the U1A-SL2 RNA complex.  
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Figure 2.8 Preliminary structure-activity relationship analysis.  a) Structure of hit compounds 
and analogues.  b) Fluorescence anisotropy was used to evaluate the ability of analogs of 
compounds 5 and 8 to destabilize the Sex lethal-tra RNA complex.  c) EMSA was used to 
evaluate the ability of compound 7a to destabilize the U1A-SL2 RNA complex. 
 
2.2.9 Structure-Activity Relationships  
 A preliminary structure activity relationship analysis was performed. The core of 
compound 7 is a disulfonated stilbene, which could possibly mimic a diphosphate of RNA.  
Hamy and coworkers identified a similar disulfonated stilbene compound (CGA127053) as an 
inhibitor of Tat protein-TAR RNA complex (Figure 2.9).17  They also found that Ba12330, 
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which does not have the acetoacetate group, had significantly lower activity.  We evaluated an 
analog (7a), which does not have catechol moieties, against U1A-SL2 RNA complex (Figure 
2.6).  Similar to the finding in the report of Hamy et al. the core molecule itself does not inhibit 
the U1A-SL2 RNA complex.  This suggests that the core moiety does not promiscuously bind to 
any nucleotide binding protein and the auxiliary functional groups are necessary for the binding 
affinity and may determine the selectivity of the compound. 
 
 
Figure 2.9 Sulfonated stilbene compounds identified by Hamy et al. that are active 
(GCA147053) and inactive (Ba12330) against the Tat-TAR RNA complex.17 
 
 Arylstibonic acids have been reported to inhibit several DNA binding proteins.40,41  The 
stibonic acid group of compound 5 has been thought to mimic a phosphate group for its activity 
against apurinic/apyrimidinic endonuclease 1.37  To determine that possibility, we synthesized a 
phosphonic acid analog (5c), a sulfonic acid analog (5d), and a carboxylic acid analog (5e) of 
compound 5 and evaluated these compounds as inhibitors of the Sex lethal-tra RNA complex.  
However, none of the compounds destabilize the complex.  This result suggests that the larger 
size of antimony and the ionic state of the stibonic acid may be critical for inhibitory activity.  
The results obtained with compounds 5a and 5b indicate that both stibonic acid and the acrylate 
moiety are required for activity.   
 Several analogs of compound 8 were also evaluated. Compound 8e at 100 µM 
concentration results in 32% inhibition of Sex lethal-tra RNA complex, while the other analogs  
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(8a, 8b, 8c, and 8d) showed negligible inhibition.  Therefore all four groups of the benzene ring 
are important for its optimal inhibitory activity. 
 
2.3 Conclusion 
 In conclusion, we have identified three distinct compounds, compounds 5, 7, and 8 that 
inhibit RRM-RNA interactions.  Compound 5 selectively inhibits the Sex lethal-tra RNA 
complex and is the first example of an inhibitor of a complex formed between an unstructured 
single-stranded RNA and a protein. Compound 7 selectively inhibits the U1A-SL2 RNA 
complex.  All three compounds bind to the protein, instead of the RNA. Considering the fact that 
RRMs bind to single-stranded RNA and most of the RNA targets are unstructured, targeting the 
protein could be a promising approach for disrupting RRM-RNA interactions.  Binding small 
molecules to flexible, unstructured sequences of RNA is a significant challenge.  Furthermore, 
compounds that can specifically bind to different RRMs may be used to probe the role of each 
RRMs within the same protein.  In fact, Meisner and coworkers have identified compounds that 
specifically bind to RRM3 of HuR protein and used those compounds to assign the specific 
function of RRM3.22  Further analysis of the ability of these three compounds and analogs to 
destabilize different complexes formed between RNA and RRM-containing proteins may give 
insight into which functional groups on the molecules are important for specific binding.  These 
compounds provide a basis for the design of new probes for RRM-containing proteins.   
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2.4 Materials and Methods 
Materials 
 Compounds for the initial screen were obtained from the high-throughput screening 
facility at University of Illinois at Urbana-Champaign.  28 compounds for the second screen 
were obtained from NCI and purchased from Hit2Lead and confirmed with mass spectrometry 
(ESI).  Analogs 5c, 5d and 8e were synthesized and the other analogs were purchased from 
Sigma-Aldrich and TCI America.  All RNAs were purchased from Integrated DNA technology 
(IDT) and purified using denaturing-PAGE. 
 
Protein expression and purification 
His6-containing plasmids were transformed into Escherichia coli strain BL21DE3 
(pLysS) competent cells.  The cells were grown in LB medium, and protein expression was 
induced with 1 mM IPTG at OD600=0.60.  The cultures were grown for 5–6 h after induction.  
The cells were pelleted, resuspended in 10 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
20 mM imidazole, pH 7.6) and lysed by ultrasonication.  The lysate was centrifuged at 10,000 
rpm and the supernatant was loaded on a 1 mL Ni-NTA column, and the protein was eluted with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 7.6).  Eluted protein 
was dialyzed against storage buffer (Sex lethal: 20 mM HEPES, 25 mM KCl, 1 mM β-
mercaptoethanol, 1 mM EDTA; U1A: 10 mM potassium phosphate, 50 mM KCl) and 
concentrated by amicon filter MWCO 3,000.  The protein concentration was determined by UV 
spectroscopy and the extinction coefficient obtained by amino acid analysis (Yale Keck facility).  
The protein identity was confirmed by low-resolution electrospray ionization mass spectrometry 
and the purities of the proteins were assessed by SDS-PAGE.  Sex lethal (F256W) was made by 
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site-directed mutagenesis and was expressed and confirmed as the WT protein.  The 
concentration of the Sex lethal (F256W) was determined using BCA assay (Pierce). 
 
Fluorescence anisotropy  
 A 5'-fluorescein labeled 11mer tra RNA (5'-UGUUGUUUUUUUU-3') was used for the 
fluorescence anisotropy experiments.  To assess the binding affinity of Sex lethal protein-tra 
RNA complex, a varying amount of Sex lethal was incubated with 3 nM tra RNA in a buffer 
solution of 15 mM HEPES, pH 7.4, 50 mM KCl, 1 mM EDTA, 1 mM , β-mercaptoethanol and 
0.01% Triton X-100.  The raw anisotropy values at different concentration of Sex lethal protein 
were fit to equation 1 to obtain the Kd value. 
 
€ 
y =max 1
1+ Kdx
     Eq. 1 
 
 For the high-throughput screen, the concentrations of Sex lethal and 11-mer tra RNA 
were adjusted so that 80% binding was achieved.  Final concentration of Sex lethal and tra RNA 
were 0.5 µM and 3 nM in a buffer solution of 15 mM HEPES, pH 7.4, 50 mM KCl, 1 mM 
EDTA, 1 mM , β-mercaptoethanol and 0.01% Triton X-100. 2 µL of compound solutions in 
DMSO (1 mM) were added to 38 µL of complex solutions in a 384 well plate.  For the negative 
control 2 µL of DMSO was added.  A RNA only sample was used as a positive control.  The 
solution was incubated at room temperature for 1 h and the fluorescence anisotropy was 
measured using Analyst HT (Molecular Devices) with an excitation filter of 485 ± 10 nm and an 
emission filter of 530 ± 10 nm.  The anisotropy was calculated by equation 2, where r is the 
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anisotropy value, G is the G factor,  is the fluorescence intensity with parallel-oriented and  
is the fluorescence intensity with perpendicular-oriented excitation and emission polarizers. 
	  
€ 
r = (I// − I⊥)(I// + 2GI⊥) 	  
	   	   	   	   	   	   	   Eq. 2 
The percent inhibition was calculated with equation 3, where r is the anisotropy value of the 
sample, RO is RNA only and NC is the negative control. 
 
€ 
1− r − RONC − RO
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ ×100       Eq. 3    
The second screen was performed using the same condition except with a higher concentration of 
Triton X-100 (0.1%).  The second screen was repeated three times.  Analogs of the compound 5 
and compound 8 were tested in the presence of 0.01% Triton X-100, 100 µM compound, and 
RNA 3 nM. 
 
Electrophoresis mobility shift assay (EMSA) 
Sex lethal-tra RNA. 0.1 µM of protein was incubated with 400 pM 32P-labeled RNA and varying 
amounts of compounds for 2 hours at 4 °C in a buffer containing 15 mM HEPES, pH 7.4, 50 
mM KCl, 1 mM EDTA, 1 mM β-mercaptoethanol, 20 % glycerol, and 0.01~0.5 % Triton X-100.  
Electrophoreses were carried out at 4 °C for 45 minutes at 320 V with 0.5X TBE as running 
buffer.  The gels were pre-run at 320 V for 30 minutes before loading 10 µl of reaction mixture 
per well.  The native gels, 6% acrylamide 80:1 (acrylamide : bisacrylamide), were poured 
twenty-four hours in advance or a minimum of two hours before running and left to equilibrate in 
a cold room at 4 °C. 
 
! 
I//
! 
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U1A-SL2. 5 nM of protein was incubated with 50 pM 32P-labeled RNA and varying amounts of 
compounds for 40 minutes at room temperature in a buffer containing 10 mM Tris pH 7.4, 250 
mM NaCl, 1 mM EDTA and 0.5% Triton X-100.  Electrophoreses were carried out at 25 °C for 
30 minutes at 350 V with 1X TBE as running buffer.  The native gels, 8% acrylamide 42:1 
(acrylamide : biacrylamide), were pre-run at 350 V for 30 minutes before loading 10 µl of 
reaction mixture per well.  
The gels were exposed by autoradiography (Molecular Dynamics) and analyzed with 
Quantity One (Biorad) software.  The gels were repeated three times for each compound.  The 
data were fit to equation 4, using Prism v5.0 to obtain IC50 values.  is the concentration of the 
compound added, h is the hill slope, max is the maximum binding without the compound, and 
min is the minimum binding. 
 
€ 
y =min+ max−min1+10(x− log IC50 )h
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟             Eq. 4 
Inhibitory constant Ki was calculated using equation 5, where [P]T is the concentration of the 
protein. 
	  
€ 
Ki =
IC50
([P]T /Kd ) −1
       Eq. 5 
 
Fluorescent binding experiments 
All fluorescence data was obtained using a temperature controlled Horiba Jobin Yvon 
fluorimeter with a 250 µL cell with a 3 mm path.  The buffer used was 15 mM HEPES, pH 7.4, 
50 mM KCl, 1 mM EDTA, and 1 mM β-mercaptoethanol. 
 
! 
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RNA binding experiment. 5'-fluorescein labeled 11mer tra RNA was used for the RNA binding 
experiments.  To a 200 µL solution of 100 nM tra RNA, 1 µL of concentrated samples of 
compounds (200 µM, 400 µM, 800 µM, 1.6 mM and 3.2 mM) in DMSO was added for each 
titration.  After 1 min, the fluorescence was measured with an excitation wavelength of 485 nm 
(slit width of 5 nm) and emission wavelength of 520 nm (slit width of 5 nm).  A control 
experiment was performed by adding DMSO to the free RNA solution.  
 
Protein binding experiment. For the binding assay with Sex lethal protein, a cell sample (200 
µL) of 2 µM Sex lethal (F256W) was excited at 295 nm (slit width of 4 nm) and emission 
recorded between 310-450 nm (slit width of 8 nm), monitoring the maximum at 355 nm.  1 µL of 
concentrated samples of compounds (200 µM, 400 µM, 800 µM, 1.6 mM and 3.2 mM) in 
DMSO was added for each titration.  The sample was then allowed to equilibrate for 1 min and 
the fluorescence was measured.  The decrease in fluorescence with increasing concentration of 
compound was monitored until the fluorescence change was no longer observed.  Innerfilter 
effect of the small molecules were calculated based on UV absorption measurements between 
240~600 nm of the compounds on a Shimadzu UV2450 spectrophotometer.  A control 
experiment was performed by adding DMSO to the protein solution.  The control fluorescence 
intensity was subtracted from the raw data and the innerfilter effect was corrected using equation 
6.  
 
€ 
Fcorr = Fobs⋅ 10
ODex +ODem
2
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ 
      Eq. 6 
The innerfilter effect corrected fluorescence data were fit to equation 7, using Graphpad Prism 
v5.0 to obtain apparent equilibrium dissociation constants (Kd).  F is the fluorescence intensity of 
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the sample, F0 is the initial fluorescence intensity, Ff is the final fluorescence intensity,  is the 
concentration of compound added, and h is the hill slope. 
 
€ 
F − F0
Ff − F0
=max x
h
Kd h + x
      Eq. 7 
 
Tryptophan control. To a 200 µL solution of 2 µM Tryptophan, 1 µL of concentrated samples of 
compounds (200 µM, 400 µM, 800 µM, 1.6 mM and 3.2 mM) in DMSO was added.  The 
measurements were performed as the protein binding experiment.  The plot is an average of two 
independent measurements. 
 
Dynamic light scattering (DLS) 
 Compounds were dissolved to 20 mM in DMSO and diluted with filtered 15 mM HEPES 
buffer (pH 7.4) to a final concentration of 500 µM.  Solutions of the compounds were analyzed 
using ZetaPals instrument (Brookhaven Instruments Corporation) equipped with helium-neon 
laser at 658 nm.  Scattered light is collected at an angle of 90° by a photon-counting 
photomultiplier tube and is then directed to a correlator.  The software (BIC particle sizing) 
derives particle sizes from the correlator function.  Each compound was measured three times or 
more at room temperature. 
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Synthesis of 5c, 5d and 8e 
(E)-3-(3-phosphonophenyl)acrylic acid (5c)  
 
 
 
(E)-tert-butyl-3-(3-bromophenyl)acrylate (5c-1).  
5c-1 was obtained from a Wittig reaction between 3-bromobenzaldehyde and (tert-
butoxycarbonylmethylene) triphenylphosphorane.42  3-bromobenzaldehyde (1.0 mmol, 185 mg) 
and (tert-butoxycarbonylmethylene) triphenylphosphorane (1.5 mmol, 565 mg) were stirred in 
water at 90°C for 2 h.  After cooling the reaction mixture to room temperature, the product was 
extracted from the water layer with CH2Cl2 (3 × 5 mL) and the combined organic layers were 
dried over sodium sulfate, filtered and concentrated under vacuum.  The crude product was 
purified using flash column chromatography (5% ETOAc/hexane) to give 55% (155 mg) of 5c-1 
(E/Z ratio: 92/8). 1H NMR (400 MHz, CDCl3) δ 7.63 (t, aromatic, 1H), 7.47 (d, CHβ=CHα, 
P
H
O
OO tButBuH
O
Br
+
PPh
Ph Ph
O
O
O
O
Br
+
P
O
O O tButBu
O
O
P
O
HO OH
OH
O
H2O, 90ºC
reflux
(Ph3P)4Pd(0)
TEA
TFA
5c-1
5c-2 5c
O
O
Br
	   70	  
J=16.0 Hz, 1H), 7.47-7.22 (m, aromatic, 3H), 6.34 (d,  CHβ=CHα, J=16.0 Hz, 1H), 1.53 (s, 
(CH3)3CO, 9H). 
 
  
(E)-tert-butyl 3-(3-(di-tert-butoxyphosphoryl)phenyl)acrylate (5c-2). 
5c-1 and di-tert-butylphosphite were coupled using Pd(PPh3)4.43  In a disposable tube with screw 
cap was placed 5c-1 (0.55 mmol, 155 mg), di-tert-butylphosphite (0.66 mmol, 128 mg), 
Pd(PPh3)4 (0.027 mmol, 31.7 mg) and 250 µL of dry TEA/toluene (1:1).  The reaction mixture 
was stirred under nitrogen at 80°C overnight.  White precipitate was formed 1 h after the reaction 
mixture reached 80°C.  The reaction mixture was cooled to room temperature and filtered.  The 
filtrate was concentrated under vacuum.  The residue was purified by flash column 
chromatography on silica gel, eluting with ETOAc/hexane (1:1) yielding 43.2 mg (20%) of 5c-2.  
1H NMR (500 MHz, CDCl3) δ 7.91 (d, aromatic, 1H), 7.76 (m, aromatic, 1H), 7.60 (d, aromatic, 
1H), 7.60 (d, CHβ=CHα, J=16.0 Hz, 1H), 7.42 (m, aromatic, 1H), 6.42 (d, CHβ=CHα, J=16.0 Hz, 
1H), 1.53 (s, (CH3)3CO, 9H), 1.46 (s, 2×(CH3)3PO, 18H). 
 
 
(E)-3-(3-phosphonophenyl)acrylic acid (5c)  
P
O
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5c-2 (0.11 mmol, 43.2 mg) was treated with 40% TFA/CH2Cl2 solution for 2 h.  The precipitate 
was filtered, washed with CH2Cl2 and dried under vacuum to give 16.5 mg (67%) of 5c. 1H 
NMR (500 MHz, DMSO-d6) δ 7.85 (m, aromatic, 2H), 7.69 (m, aromatic, 1H), 7.62 (d, 
CHβ=CHα, J=16.0 Hz, 1H), 7.51 (m, aromatic, 1H), 6.53 (d, CHβ=CHα, J=16.0 Hz, 1H). 
 
m-Sulfocinnamic acid (5d)44 and 3-amino-1,2-benzenediol (8e)45 were synthesized as 
previously described.  
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CHAPTER 3 
Electrostatic Interactions and Conformational Selection in  
Two-step U1A-SL2 RNA Dissociation Kinetics 
The work in this chapter would not have been possible without the help of Irisbel Guzman, who 
has contributed greatly to this project. 
 
3.1 Introduction 
3.1.1 Dynamics of Protein-RNA complex formation 
 In nearly all protein-RNA complexes that have been characterized, structural changes are 
seen in both protein and RNA.  Ribosomal proteins, including L11 and L30 have been shown to 
exhibit an induced fit mode of binding.  The target RNAs of these proteins, also show a high 
degree of conformational change upon binding.  NMR studies and fluorescent studies using Trp 
mutants of human tristetrapolin have suggested that both induced fit and conformational 
selection are important for the protein to bind the target AU rich RNA.1,2  In the case of 
aminoacyl-tRNA synthetase, precise recognition of the cognate tRNA is achieved by 
electrostatic interactions with discriminating functional groups on the tRNA bases as well as the 
dynamics of the protein and tRNA.3  Sequence dependent tRNA conformations are specifically 
recognized by the protein, and further conformational adjustments of the protein have been 
observed.3    Together, these examples emphasize that the dynamics of the protein and the RNA 
are crucial factors for determining the binding mechanism, affinity, and specificity of the 
protein-RNA complexes. 
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3.1.2 Dynamics of U1A-SL2 RNA complex 
 Helix C, loop1 and loop 3 of the U1A protein undergo conformational rearrangements to 
form the complex.  The NMR structure of the free U1A protein shows that helix C is positioned 
across the β-sheet, which is the primary RNA binding surface.  In the U1A-RNA complex, helix 
C is moved away from the β-sheet surface, allowing the residues in the β-sheet to contact the 
SL2 RNA.  Several experiments have suggested that although the NMR structure has captured 
the closed helix C conformation, in solution the helix C may be dynamic.4,5  Jean and coworkers 
have suggested that the movement of helix C is on a nanosecond or a longer timescale.5  
 Loop 3 is flexible in the free form and becomes rigid upon binding to the RNA, and 
protudes through the loop region of the SL2.6,7  This conformational change presents the RNA 
bases to the β-surface of the protein forming a stable complex.  Molecular dynamics (MD) 
simulations have shown that the mutation of Gly53, which is located at the junction of loop 3 and 
β3, to a Val significantly reduces the mobility of loop 3 and results in a lower binding affinity.8  
In addition, correlated motions of loop1, loop 3 and helix C are proposed to be important for the 
U1A-SL2 complex formation.8   
  Although the structure of the free RNA has not been determined, NMR studies have 
suggested that the chemical shifts of many protons for bound RNA are substantially different 
from those for free RNA, especially in the loop region of the RNA.  Molecular dynamics 
simulations have shown the SL2 RNA is dynamic in the absence of the U1A protein and 
becomes more ordered upon binding to the RNA.9-11  The bases of the loop region are mostly, 
but not always, facing the interior of the RNA.  Therefore, a conformational selection may be 
occurring to some extent during the association with the protein.   
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3.1.3 Kinetics of U1A-SL2 RNA complex dissociation 
 Dynamic processes involved in the association and dissociation of protein-RNA 
complexes can be probed by detailed kinetic studies.  The kinetics of association of the U1A and 
SL2 RNA complex has been studied using surface plasmon resonance (SPR).12-15  By comparing 
the rate of association and dissociation of the complexes of the wild type and mutant proteins, a 
'lure and lock' mechanism of binding was proposed.12  Like other macromulecular recognition 
processes, an initial association of the complex that is dominated by electrostatic interactions is 
followed by conformational rearrangements to form the tight complex.  Mutation of positively 
charged residues increased the rate of association and the mutation of residues that have key 
stacking interaction with the RNA decreased the rate of dissociation.  This data supports the 
importance of positively charged residues in the initial 'lure' step and the stacking residues in 
complex stability.  Additional SPR studies have each revealed the role of the Tyr13-Phe56-Tyr13 
network and loop 3 in the U1A-SL2 association pathway.   
 More recently, Anunciado et al. have developed a two-step pathway for the dissociation 
between U1A and SL2 RNA based on data obtained from temperature jump and stopped flow 
experiments.16  In this pathway the first fast step of ~100 µs is the loosening of the U1A-SL2 
RNA complex and the second slow step of ~233 ms is the actual dissociation of the complex.   
 
3.1.4 Electrostatic interactions in protein-RNA complexes  
 Electrostatic interactions mediated by basic residues in RNA binding proteins are 
important for overall protein-RNA binding affinity and may also play a role in specificity of 
these complexes.17  Indeed, a computational study has shown that the largest overlap between a 
positive electrostatic patch and the binding surface is observed with a RNA binding protein, L1 
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ribosomal protein.18  Large and small positively charged surfaces of RNA binding proteins are 
critical during short- and long-range interactions that lead to binding.  A positive patch in the 
center of the aminoacyl-tRNA synthetase has been suggested to play an important role in long-
range interactions with the cognate tRNA, which is the decisive factor of primary 
association.19,20  The aminoacyl-tRNA synthetase and the tRNA are brought together when the 
negative potential of the tRNA fits the positive potential patch of the enzyme.20 
The net charge of the N-terminal RRM of the U1A protein is +7 while that of the C-
terminal RRM is 0.21  Many of the positively charged residues are missing in the C-terminal 
RRM or replaced by a negatively charged or a neutral residue.  This difference may contribute to 
the fact that the C-terminal RRM does not bind to RNA, while the N-terminal RRM binds to SL2 
RNA with a sub-nanomolar Kd.22  A similar trend was found in a mouse neural protein, 
Musashi1.  Musashi1 contains two RRMs, but only the N-terminal RRM binds to the target RNA 
with high specificity.23  The positive potential is prevailing for the β-sheet surface of RRM1, 
while the β-sheet surface of RRM2 is largely neutral with small negative potential patches.  
Considering the fact that the overall structural fold is essentially identical for RRM1 and RRM2, 
the positive electrostatic potential of the RRM1 is thought to play a significant role in RNA 
binding.23 
The role of basic residues in the N peptide (derived from N protein in phage λ) and box B 
RNA complex has been studied using parallel experimental measurements and theoretical 
calculations.  Calculations based on the non-linear Poisson-Boltzmann equation revealed that all 
basic residues of the peptide contribute significantly to the overall binding free energy, but the 
relative contributions vary depending on the environment of a residue.17   
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 Here, we studied the role of four lysines during the two-step U1A-SL2 RNA complex 
dissociation kinetics. We performed laser-induced temperature jump and stopped-flow kinetics 
experiments with tryptophan-labeled mutants of U1A.  We found that Lys20, Lys23 and Lys50 
are crucial for the formation of a tight complex between U1A and SL2 RNA: the fast phase (τ1) 
associated with tight binding disappears when these residues were mutated to glutamine.  
Stopped flow kinetics of these mutants reveals no significant change in the slow phase (τ2) 
associated with dissociation of the loosely bound state.  In contrast, mutating Lys22 had no effect 
on the fast kinetics of the tight complex, but the slow phase (τ2) sped up, implying that Lys22 is 
important for the stability of the loose complex.  Interestingly, a fast phase of ~27 ms with 
negative amplitude was resolved in a temperature jump experiment with U1A Lys22Gln without 
RNA.  We propose that this negative fast phase monitors a conformational transition of U1A 
similar to that which occurs upon tight RNA binding.  If so, the Lys22Gln mutant is closer to 
conformational selection than the wild type in the continuum from conformational selection to 
induced fit. 
 
3.2 Results 
3.2.1 Selection of mutated positively charged residues  
 We used a 101-amino acid N-terminal U1A fragment that has been shown to be sufficient 
for high affinity binding to SL2 RNA.  The Trp fluorescent label for the kinetics studies was 
introduced into the Phe56 position.  Phe56 forms a stacking interaction with A6 of the SL2 RNA 
in the complex.7  This Phe56Trp mutation was previously reported to have only minimal effects 
on binding affinity and was successfully used to monitor the dissociation of the U1A-SL2 
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complex.5,24 The titration of SL2 RNA to the U1A (F56W) solution quenches the Trp 
fluorescence presumably due to the stacking interaction between the Trp and the A6.16  
  
Figure 3.1  a) Stereoview structure of the U1A-SL2 complex.  Mutant residues are indicated in 
different colors.  K20 is shown in yellow, K22 in green, K23 in blue and K50 in red. Black solid 
lines show the electrostatic interactions of the lysine residues with the closest phosphate group in 
the SL2 RNA. Distances from each lysine residue to the closest phosphate group of SL2 RNA 
are K20: 6.6Å (C-2); K22: 4.1Å (A-4); K23: 7.7Å (C9); K50: 7.7Å (U3).  The structure was 
generated with the program Chimera.25  b) Sequence of SL2 RNA. Nucleotides that are directly 
recognized by the protein are shown in red.  c) Sequence of the N-terminal RRM of U1A protein.   
 
 To analyze the role of electrostatic interactions in the two-step dissociation pathway 
observed with U1A (Phe56Trp)-SL2 complex, four lysine residues, Lys20, Lys22, Lys23 and 
Lys50, presented in Figure 3.1a and c, that have electrostatic interaction with RNA, but do not 
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form hydrogen bond with the RNA, were chosen for mutation.  The residues were mutated to 
glutamine to conserve the relative size of the residue while eliminating the positive charge. 
 Previous studies have shown that all four of these residues have an effect on the 
association of the complex using surface plasmon resonance.12,15 Whereas other positively 
charged residues that are located on the top of the protein (Arg7, Lys60 and Arg70) did not show 
a significant difference from the wild type.15  In the U1A-SL2 complex, Lys20 is close to the 
upper part of the RNA stem, while Lys 22 lies near the bottom tip of the RNA stem.  Lys23 has 
electrostatic interaction with the phosphate groups of C9 and C10 in the loop region.  Lys50 also 
has electrostatic interactions with the phosphate groups in the loop region.  However it is closest 
to the phosphate groups of U3 and G4.  Therefore, these four residues participate in electrostatic 
interactions with different parts of the RNA phosphate backbone. 
 
3.2.2 Determination of optimal dissociation conditions 
 To determine the optimal conditions for the kinetic analysis with stopped-flow and 
temperature-jump, we measured the equilibrium binding affinity of each of the mutant U1A 
proteins using an electrophoretic mobility shift assay (Table 1).  At 25 °C and 200 mM KCl, all 
of the Lys to Gln mutations decreased the binding affinity compared to the F56W mutant.   The 
mutation of Lys22 and Lys50 each decreased the binding affinity more than 14-fold.  Lys20Gln 
and Lys23Gln had a less significant effect on the binding affinity, only a ~3-fold and ~6-fold 
decrease, respectively.  The same trend was previously observed by another lab.7   
 For the temperature jump experiment, we analyzed the binding affinity at 25 °C and 35 
°C.  The higher temperature decreased the binding affinity of U1A (Phe56Trp) ~5-fold, which is 
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sufficient to induce dissociation.  The other mutants also showed decreased binding affinity at 
higher temperature.   
 In the stopped-flow setup, two solutions are rapidly mixed together.  For complex 
dissociation, one syringe was filled with the protein-RNA complex, and the other was filled with 
buffer.  Therefore either the binding affinity of the complex has to be weak enough to dissociate 
with two-fold dilution, or we can use a high concentration of salt in the buffer syringe to drive 
dissociation.  Based on the binding affinity of U1A (Phe56Trp), we decided to jump the salt 
concentration from 0.2 to 1 M KCl for dissociation.  The increase of salt concentration decreased 
the binding affinity from 22 (±1)  nM to 110 (±20) nM, sufficient for dissociation.  The effect of 
KCl concentration on the Kd values of the other mutants was smaller.  The loss of binding 
affinity ranged from 1.3-fold to 3.3-fold.   The two-fold dilution of the complex solution and the 
slight decrease in binding affinity at 1 M KCl still dissociated those complexes, as shown in the 
stopped-flow section. 
 
Table 3.1  Kd values of mutant U1A proteins. 
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3.2.3 Circular dichroism measurements  
 To confirm that the secondary structure does not change upon temperature jump we 
evaluated the structures of the U1A mutants using circular dichroism.  Each mutant was 
measured at 25 °C and 45 °C, because the higher temperature jump was performed from 35 °C to 
45 °C.  The CD spectra for all of the mutants were similar to the pseudo wild type control  
(Phe56Trp) at each temperature and overlapped almost perfectly between the two temperatures 
(Figure 3.2), indicating that the substitution of Lys for Gln and the temperature jump do not 
introduce perturbation of the secondary structure of the protein.  Therefore, any fast phase 
observed during temperature jump is not due to protein unfolding. 
 
 
Figure 3.2 Circular dichroism of U1A mutants. a) K20Q/F56W b) K22Q/F56W  c) K23Q/F56W  
d) K50Q/F56W.  10 µM solution of each proteins was measured in sodium cacodylate buffer. 
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3.2.4 Temperature jump measurements  
 To monitor the earliest step of RNA-protein complex dissociation, Irisbel Guzman 
performed laser-induced temperature jump experiments. Our probe signal was the Trp 
fluorescence decay change χ, normalized from 1 (pre-jump) to 0 (post-jump).  The protein-RNA 
complex solution in a 200 mM KCl buffer was perturbed by temperature jumps from 25 °C to 35 
°C and from 35 °C to 45 °C (See Methods for more details of data analysis).  A single phase with 
a relaxation time of ~35 µs and a positive amplitude was observed for the Phe56Trp mutant 
complex (Figure 3.3).  
 
 
Figure 3.3 Temperature jump of 20 µM F56W  a) From 25 °C to 35 °C  b) From 35 °C to 45 °C 
 
 The Lys22Gln/Phe56Trp mutation had no effect on the fast phase, other than a slightly 
longer relaxation time (Figure 3.4c and d).  The fast phase did not significantly change with 
temperature between 35 and 45 °C.  This is consistent with the same transition from a tight 
complex to a loosely bound RNA-protein complex that was observed for Phe56Trp here and 
previously reported by Anunciado et al.16  Our observation implies that the positive charge of 
Lys22 is not required for tight complex formation.  
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Figure 3.4 Temperature jumps of K22Q/F56W mutant in 200 µM KCl buffer.  a) T-jump of just 
K22Q/F56W from 25 °C to 35 °C.  b) T-jump of just K22Q/F56W from 35 °C to 45 °C for just 
20 µM F56W mutant.  c) T-jump of 20 µM K22Q/F56W-SL2 RNA complex from 25 °C to 35 
°C.  d) T-jump of 20 µM K22Q/F56W-SL2-RNA from 35 °C to 45 °C. 
 
 However, we did not observe the fast phase with the Lys20Gln/Phe56Trp, 
Lys23Gln/Phe56Trp and Lys50Gln/Phe56Trp mutants (Figure 3.5).  Therefore these mutations 
disrupt the equilibrium between the tightly and loosely bound complex.  As control experiments, 
Lys20Gln/Phe56Trp, Lys23Gln/Phe56Trp and Lys50Gln/Phe56Trp mutants were temperature 
jumped without RNA, and no fast phase was observed.  In contrast, the temperature jump of 
Lys22Gln/Phe56Trp with no RNA has a negative fast phase of ~27 µs shown in Figure 3.4a and 
b.  Although this phase has the opposite amplitude, it has a similar time scale as the conversion 
between tight and loose U1A-SL2 complexes.  The fast negative phase in Lys22Gln/Phe56Trp is 
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evidence for a conformation transition of the protein on a similar time scale as the 
conformational transformation upon loose-tight bound complex interconversion. 
 
Figure 3.5 Temperature jump of 20 µM U1A-SL2 RNA complexes at 25 °C and 35 °C.  a) 
K20Q/F56W  b) K23Q/F56W  c) K50Q/F56W  
 
3.2.5 Stopped-flow kinetics measurements 
 To measure the complete dissociation kinetics for the positively charged mutants, Irisbel 
Guzman performed stopped-flow measurements of protein-RNA complexes.  Try56 fluorescence 
intensity between 320-450 nm was monitored as the probe.  The stopped-flow results after fast 
mixing of RNA-protein complex with 1 M KCl buffer are shown in Figures 3.6 to Figure 3.9.  
Under these conditions, the dissociation rate should dominate the relaxation process.  A single 
phase on the millisecond time scale was observed upon fast mixing for the complex dissociation 
of Lys20Gln/Phe56Trp, Lys22Gln/Phe56Trp, Lys23Gln/Phe56Trp and Lys50Gln/Phe56Trp 
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mutants.  The dissociation rate of the Lys22Gln/Phe56Trp-SL2 complex was somewhat faster 
than that of the other mutants and the pseudo wild type control (Table 3.2). 
The fluorescence amplitude increased almost to the protein-only baseline for all of the 
mutants, indicating nearly full dissociation of the complex.  The data was fit by a single 
exponential function and τ2 was not concentration-dependent (Table 3.2).  These observations 
are consistent with the unimolecular complex dissociation rate dominating over bimolecular 
association kinetics under our buffer conditions.  As shown in Figure 3.7 and Figure 3.9, the 
dissociation time τ2 increases 10-fold upon heating by 10 °C for all the mutants. 
 
Table 3.2  Relaxation time (τ2) of U1A mutants measured by sttoped-flow. 
 
 
*Unit is second.  τ2 was determined using single exponential equation. 
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Figure 3.6 Stopped-flow measurements of 1 µM U1A-SL2 RNA complexes at 25 °C.  a) 
K20Q/F56W  b) K22Q/F56W  c) K23Q/F56W  d) K50Q/F56W  
 
 
 
Figure 3.7 Stopped-flow measurements of 1 µM U1A-SL2 RNA complexes at 35 °C.  a) 
K20Q/F56W  b) K22Q/F56W  c) K23Q/F56W  d) K50Q/F56W  
 89 
 
Figure 3.8 Stopped-flow measurements of 0.5 µM U1A-SL2 RNA complexes at 25 °C. 
a) K20Q/F56W   b) K22Q/F56W  c) K23Q/F56W  d) K50Q/F56W. 
 
 
 
Figure 3.9 Stopped-flow measurements of 0.5 µM U1A-SL2 RNA complexes in at 35 °C.   
a)  K20Q/F56W  b) K22Q/F56W  c) K23Q/F56W  d) K50Q/F56W. 
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Figure 3.10 Kinetic scheme for dissociation of the U1A-SL2 complex.  a) K22Q mutation does 
not affect the overall kinetic scheme.  b) K20Q, K23Q and K50Q mutants do not form the tight 
complex.  Trp56 is shown in orange and the other mutations are indicated as in Figure 3.1.  
 
3.2.6 Global fit of the data 
 To support our hypothesis of a two-step dissociation pathway (
€ 
PRtight →PRloose →P + R), 
Professor Martin Gruebele performed a global fit of the kinetics and thermodynamics data for the 
F56W mutant.  He used a similar approach as previously reported by Anunciado et al.16  He 
simultaneously fitted the temperature jump, stopped-flow and EMSA binding data at all 
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temperatures measured.  The global fit yielded activation free energies and the equilibrium free 
energies for each reaction step during dissociation, as well as linear free energy dependences on 
temperature and salt concentration, modeled by 
 
   
€ 
ΔG = ΔG0 + ΔGT (T −T0) + ΔGKCl KCl[ ]      Eq. 1 
 
For the first step of dissociation (
€ 
PRtight →PRloose ) we obtained ΔG0 = 5.29 kJ/mole, and ΔGT = -
0.608 kJ/mole.  The calculated 
€ 
ΔGT shows that the tightly bound complex is destabilized by 
temperature faster than the loosely bound complex.  For the second step (
€ 
PRloose →P + R), we 
obtained 
€ 
ΔG0  = 9.97 kJ/mole, 
€ 
ΔGT  = -0.07 kJ/mole, and 
€ 
ΔGKCl  = -23.1 kJ/mole.  Thus complete 
dissociation is favored at higher temperatures and higher salt concentrations.  The activation 
energies were fitted to equation 
     
€ 
kAB = k0e−ΔG
†AB /RT      Eq. 2 
 
The prefactor was fixed to km=(0.01 η(T))-1 ms-1, using the normal Kramers viscosity dependence 
for both reactions.26  The activation energies are 
€ 
ΔGtight→ loose† =  8.76 kJ/mole and 
€ 
ΔGloose→ dissociated†
= 34.2 kJ/mole for the second step.  No temperature dependence of the activation free energy 
was fitted because only two temperatures were measured.  The actual barriers may be 
correspondingly higher if the diffusional prefactor is faster; if both reactions have a similar 
prefactor (as assumed here), complete dissociation has a significantly higher activation barrier 
than tight-loose interchange.  The free energy landscape for tight binding and dissociation is 
shown in Figure 3.11. 
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3.3 Discussion 
 Combining the temperature jump and stopped-flow data from pseudo wild type Phe56Trp 
and the Lys to Gln mutants we confirmed the two-step dissociation pathway previously proposed 
by our lab (Figure 3.10a).  However for Lys20Gln, Lys23Gln, and Lys50Gln mutants a one-step 
dissociation pathway of loose complex to dissociated state was observed (3.10b).  The 
disappearance of the fast transition between tight complex and loose complex observed with the 
glutamine mutants of Lys20, Lys23 and Lys50 demonstrate that the electrostatic interactions 
mediated by these residues are required for the tight complex formation between U1A and SL2 
RNA.  These residues are close to the loop region of the RNA where majority of the contacts are 
formed between the protein and RNA.  These results suggest that the residues that contact the 
loop or close to the loop of the SL2 RNA are important for locking the RNA in position to form 
a tight complex.   
 For the Lys22Gln mutant, we observed a similar phase as the wild type control, which 
suggests that the relative energy of tight and loose energy states is similar to the wild type 
control (Figure 3.11a).  Thus, the Lys22Gln mutation did not affect the formation of the tight 
complex.  Lys22 may have a strong electrostatic interaction with A-5 of the RNA.  The distance 
between Lys22 and the phosphate backbone of A-5 is approximately 5Å, while other lysine 
residues that were mutated are 7~9Å apart.  Considering the fact that Lys22 may have the 
strongest electrostatic interaction with the protein, it is puzzling why neutralization of Lys22 did 
not affect the tight complex.  The location of the residue may be the key to explain this result.  
Lys22 is contacting the furthest end of the RNA stem, which is not where the majority of the 
contacts are formed.  Therefore we purpose that although this residue is important for the overall 
binding free energy, it is not crucial for the tight complex formation due to the region of the 
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RNA it interacts with.  Previous SPR data has shown that Lys22 is crucial for complex 
stability.15  Our stopped-flow results suggest that Lys22 contributes to the stability of the loose 
complex, holding the RNA and decreasing the rate of dissociation.  
 
Figure 3.11  Energy diagram of the two-step U1A-SL2 RNA complex dissociation.  F56W is in 
black solid line, K22Q/F56W is in green dotted line, and the other mutants are in red dashed line. 
T is tight complex, L is loose complex and D is dissociated.   
 
 Binding of a protein to its substrate is often discussed in terms of conformational 
selection vs. induced fit in an either-or scenario.27,28  Either the conformation “B” that the protein 
will occupy in the bound state is already low in free energy before the substrate binds; in that 
case the substrate can ‘select’ conformation “B”, or the free energy of “B” is high relative to the 
conformation “A” that is occupied by the free protein before substrate binding; in that case the 
substrate ‘induces’ conformation “B.”  In reality, intermediate scenarios are possible as shown in 
Figure 3.12a.27,28  In the simplest case where the conformational change is limited to the protein, 
we can describe the possible scenarios by a single parameter PSI (for Protein Selected or 
Induced): 
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Ψ =
GB (unbound) −GA (unbound)
RT = ΔGBA   Eq. 3 
 
It should be clear that for a given substrate, Ψ is a property of the protein only: knowledge of the 
free energies of protein conformations A and B is required only in the unbound state.  
Numerically, Ψ describes the possible scenarios as follows: (1) Lock-and key: if Ψ < < 0, state 
“B” is already lower in free energy and the substrate simply binds to the protein without inducing 
a conformational change; state “A” is then irrelevant. (2) Conformational selection: if Ψ ≈ 1, 
state “B” is populated even before binding and the substrate can select it over state “A.”  (3) 
Induced fit: if Ψ >> 1, state “B” has to be induced by the substrate to lower its free energy upon 
substrate binding.  Since Ψ can vary continuously from negative to positive values, scenarios 
between the three classic “either-or” scenarios are possible.  It should also be clear that Ψ cannot 
always be determined from a bulk thermodynamic experiment.  The free energy difference 
ΔGB(unbound) cannot be measured in equilibrium if GB(unbound) >> GA(unbound).  Instead, a 
kinetic experiment is required that can populate state “B” under unbound conditions. 
 Our data provides some evidence that the Lys22Gln mutation shifts Ψ from induced fit 
towards conformational selection (Figure 3.12a).  In the pseudo wild type Phe56Trp, fast kinetic 
equilibration is observed between two RNA-bound states, but tryptophan fluorescence detects no 
conformational relaxation of the protein by itself.  The Lys22Gln mutant shows a similar 
equilibration between RNA-bound states, but even without RNA the protein has a phase with a 
similar relaxation time, but opposite amplitude.  This is consistent with an equilibrium between 
two protein conformations in the absence of RNA binding, where both conformations have 
similar free energy (Ψ ≈ 1).  In that case, the tight binding site is ‘selected’ in the Lys22Gln 
mutant, but ‘induced’ in the pseudo wild type, as illustrated in Figure 3.12b.  For Lys22Gln, a 
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sign switch of the amplitude indicates that the tryptophan lifetime changes in opposite directions 
between the two conformations. 
 
 
Figure 3.12 Conformational selection and induced fit.  a) Suggested position of WT and K22Q 
mutant in the continuum of induced fit and conformational selection.  b) Energy diagram 
showing the continuum of induced fit and conformational selection.  
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 Previous MD simulations have shown two substates for free U1A protein, suggesting a 
form of conformational selection of the U1A protein upon RNA binding, although the 
conversion between the two substates was not observed in the simulation.  The time scale of 5 ns 
may not have been sufficient to reveal the conversion between the two substates.  The phase 
observed with Lys22Gln mutant is the first experimental data that suggests some extent of 
conformational selection may occur in the binding process of U1A and SL2 RNA. 
 A recent NMR study of U2AF, a splicing factor that contains two RRMs, has shown that 
U1A has two conformations with and without the target polypyrimidine tract RNA. The two 
RRMs are oriented in two different conformations: open and closed.  RNA binding shifts the 
equilibrium to the open form revealing a conformational selection mode of binding to RNA.29  
Together with our data, conformational selection may be rather a common theme in RNA 
binding proteins upon RNA binding.  Therefore a combination of conformational selection and 
induced fit may be a more accurate description of RNA binding protein binding to its target RNA 
rather than pure induced fit.  Future studies with other RNA binding proteins will provide a more 
generalized picture of the binding mechanism.   
 
3.4 Conclusion 
 Mutational studies of positively charged residues that were known to be important for 
association and complex stability of U1A and SL2 RNA support our two-step dissociation 
pathway and give new insights into the role of these residues in the complex.  We characterized 
the role of each positively charged residue by combining temperature jump and stopped-flow 
experiments using tryptophan as a fluorescent probe.  We found that depending on the position 
and distance between the positively charged residue and the RNA, the contribution to the 
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complex stability varied at each step.  Residues that interact with the loop region of the RNA are 
crucial for the stability of the tight complex whereas a residue that contacts the stem region of 
the RNA is important for the stability of the loose complex.  These results, with the results of 
previous investigations of positively charged residues, demonstrate the importance of 
electrostatic interactions between RBPs and RNA, and can be used to engineer proteins with 
tighter or looser complex populations, as well as for the design of small molecules that target one 
or both complexes. 
 
3.5 Materials and Methods 
Proteins expression and purification 
 All mutants were generated by site-directed mutagenesis and confirmed by sequencing.  
His6-containing mutant plasmids were transformed into Escherichia coli strain BL21DE3 
(pLysS) competent cells.  The cells were grown in LB medium, and protein expression was 
induced with 1 mM IPTG at OD600=0.60.  The cultures were grown for 5–6 h after induction.  
The cells were pelleted, resuspended in 10 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 
20 mM imidazole, pH 7.6) and lysed by ultrasonication.  The lysate was centrifuged at 10,000 
rpm and the supernatant was loaded on a 1 mL Ni-NTA column, and the protein was eluted with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 7.6).  Eluted protein 
was dialyzed against storage buffer (10 mM potassium phosphate, 50 mM KCl) and concentrated 
by Amicon filter MWCO 3,000.  The concentration of each protein was determined using BCA 
assay (Pierce).  Expressed proteins were confirmed by low-resolution electrospray ionization 
mass spectrometry and the purities of the proteins were assessed by SDS-PAGE.  
 
 98 
Electrophoretic mobility shift assay (EMSA)  
 Varying amounts of U1A protein were incubated with 50 pM [γ-32P] ATP-labeled RNA 
for 30 minutes at room temperature in a buffer containing 10 mM potassium phosphate (pH 7.4) 
and 1M KCl.  Electrophoreses were carried out at 25 °C for 40 minutes at 350 V with 0.5X TBE 
as running buffer.  The native gels, 8% acrylamide (42:1 = acrylamide : biacrylamide, 15 cm x 
40 cm x 1.5 mm), were pre-run at 350 V for 30 minutes before loading 10 µl of reaction mixture 
per well. The temperature of the gel was maintained at 25 °C by a circulating water bath. Gels 
were visualized on a Molecular Dynamics Storm phosphorimager.  Fraction RNA bound versus 
protein concentration was plotted and curves were fitted to the equation: Fraction bound = 
1/(1+Kd/[P]T) using KaleidaGraph (Synergy Software, PA). 
   
 
Figure 3.13 Binding curves of U1A mutants at 200 mM KCl and 25°C. a) F56W  b) 
K20Q/F56W   c) K22Q/F56W   d) K23Q/F56W  e) K50Q/F56W. 
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Figure 3.14 Binding curves of U1A mutants at 200 mM KCl and 35°C. a) F56W  b) 
K20Q/F56W c) K22Q/F56W  d) K23Q/F56W  e) K50Q/F56W. 
 
 
Figure 3.15 Binding curves of U1A mutants at 1 M KCl and 25°C. a) F56W  b) K20Q/F56W  c) 
K22Q/F56W  d) K23Q/F56W  e) K50Q/F56W. 
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Circular Dichroism (CD) 
 Thermal stability of U1A mutants were measured in a J-715 spectrpolarimeter equipped 
with a Peltier temperature control (Jasco Inc.) at 25, 35, and 45 °C.  CD spectra of 10 µM 
samples were prepared in sodium cacodylate buffer (10 mM cacodylic acid, 50 mM NaCl, pH 
7.4) in the 200−250 nm region.  Each CD spectrum in figures is an average of 50 spectra at 200 
nm/min scan speed.  A quartz cuvette (Starna Cells Inc.) with 200 mm path length was used.  
 
Laser-induced temperature jump 
 Relaxation kinetics of the U1A mutants and the equilibrated U1A–SL2 RNA in binding 
buffer (10 mM potassium phosphate, 200 mM KCl, pH 7.4) was measured with a home-built 
temperature jump apparatus described elsewhere.16  The SL2 RNA was heat-shocked before 
complexation to ensure correct secondary structure conformation and decrease significantly the 
dissociation constant (Kd). 
Laser temperature jumps of 8-10 °C were achieved using a Surelite III Q-switched 
Nd:YAG laser (Continuum Inc.)  Raman-shifted to 1.9 µm by passing the beam through a 1 m 
long tube with hydrogen gas pressurized to 300 psi.  The beam was then passed through a 50 % 
beam splitter to allow the sample to be excited from two sides providing more uniform heating.  
The pre-jump equilibrium temperature was set using an automated temperature controller, model 
Lake Shore 330 (Lake Shore Cryotronics Inc.).  The sample cell was made of fused silica tubing 
3530S-100 (VitroCom) fused shut on one side.  The fluorescence excitation path length was 0.3 
mm.  The sample was excited with a 80 MHz pulsed Ti:sapphire laser (KMLabs Inc.).  The 
Ti:sapphire laser wavelength was 860 nm, which was frequency tripled with a third harmonic 
generator (CSK Optronics Inc.) to 287 nm.  Tryptophan fluorescence was then guided from the 
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sample by an optical light-guide (Oriel Corp.), passed through a B370 band-pass filter (Hoya 
Corp.) and collected by a photomultiplier R7400U-03 (Hamamatsu Corp.).  The signal was then 
recorded and digitized every 100 ps by an oscilloscope DPO7254 (Tektronix Inc.) with 2.5 GHz 
bandwidth.  The length of the time traces was 500 µs and each trace contained many tryptophan 
fluorescence decays every 12.5 ns (80 MHz).  The temperature jump was set to occur 153.75 
µs after the oscilloscope was triggered to start data collection to provide a pre-jump baseline.  
The fluorescence decay peak signal was usually 10-40 mV.  
 
T-jump Fluorescence lifetime decays analysis 
 Relaxation kinetics data were analyzed using MATLAB (Mathworks Inc.).  Time traces 
were first binned into the intervals of 100 decays, which corresponds to 1.25 µs.  We analyzed 
the data by fitting each averaged fluorescence decay f as a linear combination of two 
fluorescence decay profiles, f =a1(t)  +a2(t) , where  is the fluorescence profile before the 
temperature jump, and  represents the equilibrated fluorescence profile after the temperature 
jump.  The parameter χ is defined by
 
 to track the progression of the 
fluorescence decay profile (i.e. change in tryptophan lifetime) from before the temperature jump  
(χ1=1), to when equilibrium has been reached again (χ1=0).  The time traces were then fitted to a 
single exponential function starting with point zero where the jump occurred. 
 
Stopped-flow 
 U1A-SL2 dissociation kinetics was monitored using fast mixing measurements 
performed using a SX-20 stopped-flow spectrometer (Applied Photophysics).  The tryptophan 
was excited at 280 nm and fluorescence emission was monitored through a 350 nm interference 
! 
f1
! 
f2
! 
f1
! 
f2
 c(t) = a1 / (a1 + a2 )
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filter (Applied Photophysics) with 2 mm entrance and exit slit width.  The fast mixing time is 
approximately 3 ms giving a dead time of ∼1 ms.  Fluorescence scans were collected in 10 s 
data files with 1000 data points.  During dissociation studies a syringe with 0.5 µM U1A–RNA 
complex solution in binding buffer (10 mM potassium phosphate, 200 mM KCl, pH 7.4) was fast 
mixed with phosphate buffer (10 mM potassium phosphate, 1.8 M KCl, pH 7.4) from another 
syringe.  A final concentration of 1 M KCl was required to obtain an optimal dissociation 
fluorescence signal.  For each sample, at least seven individual scans were average to give one 
data set.  Three independent averages were use for data analysis. 
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CHAPTER 4 
Bipartite Cysteine Display Probes for the Detection of RNA Splice Variants 
 
4.1 Introduction 
 RNA splicing is an essential process for cellular functions, and disruption of precise RNA 
splicing is often involved in diseases.  Therefore, there is a critical need for modulators of RNA 
splicing that can target specific splicing factors.  This chapter will describe a novel method to 
detect different splice products, which could lead to an assay to screen for small molecule 
activators or repressors of RNA splicing. 
 
4.1.1 RNA Splicing and diseases 
 Human genes express complex pre-mRNAs that contain exons that will make up the 
mRNA product and non-coding introns that interrupt the exons.1  Due to this nature of pre-
mRNA, RNA splicing is necessary.  The introns of the RNAs are spliced out and the exons are 
joined together to create the reading frame for translation.  In addition to constitutive splicing, 
approximately 95% of human genes are alternatively spliced, which allows a single gene to 
express multiple proteins.2  Most of alternative splicing occurs within open reading frames 
(ORFs), expanding the human proteome.  In other cases, alternative splicing occurs within 
untranslated regions and affect cis-acting elements that control mRNA stability, translation 
efficiency, and mRNA localization. Alternative splicing may also introduce premature 
termination codons, which in turn undergo nonsense-mediated decay.  RNA splicing is 
accomplished by the spliceosome, a macromolecular ribonucleoprotein complex that assembles 
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on the pre-mRNA.  The spliceosome is composed of five small nuclear ribonucleoprotein 
(snRNP) particles (U1, U2, U4, U5 and U6) and a large number of additional proteins.   
 Cis-acting elements direct the spliceosome to recognize the bona fide exons, remove 
introns, and serve as binding sites for splicing factors that regulate alternative splicing.  These 
elements are also called 'splicing code', which include the consensus splice site sequences and 
auxiliary elements known as exon and intron splicing enhancers (ESEs and ISEs respectively) 
and silencers (ESSs and ISSs respectively).1  The splicing code regulates both constitutive and 
alternative splicing.  The secondary structure of the RNA also plays a role in splicing regulation 
by sequestering sequence elements or bringing two elements into close proximity.3  Furthermore, 
the rate of transcription elongation has been shown to have an effect on alternative splicing by 
accelerating or delaying the synthesis of competing splice sites or regulatory elements.4   
 
 
Figure 4.1 Splicing codes.1 a) Consensus splice site sequences.  b) Exon and intron splicing 
enhancers and silencers. 
 
 Trans-acting elements include SR proteins and hnRNP proteins that bind to the enhancer 
and silencer sites, respectively.  These proteins communicate with other proteins to either recruit 
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or repress the activity of the spliceosome.  In addition, RNA polymerase II and transcription 
factors can directly or indirectly interact with splicing factors and either activate or repress 
alternative splicing.  Together, RNA splicing is controlled by cis-acting elements, many trans-
acting factors and other factors such as RNA structure, rate of transcription, RNA polymerase II, 
and transcription factors, which make this process highly versatile, complex, and dynamic. 
 Mutations that disrupt the splicing code or trans-acting elements can directly cause 
disease, modify the severity of the disease phenotype, or be linked with disease susceptibility.5  
Mutations in the introns as well as the exons, including those that are silent at the translational 
level, may induce exon skipping, create new exon boundaries, activate cryptic splice sites, or 
create pseudoexons.  The effects of these mutations are more direct and cause aberrant splicing 
of one gene.  However mutations in the trans-acting elements or proteins that are involved in the 
spliceosome may cause mis-splicing of mutiple genes.5  Diseases that are caused by aberrant 
RNA splicing include Duchene muscular dystrophy, cystic fibrosis, spinal muscular atrophy, 
retinitis pigmentosa, β-thalassaemia, and several types of cancer, to name just a few.5,6 
 Therefore, small molecule modulators of RNA splicing can be used as therapeutic agents 
and as tools to understand the complicated splicing regulatory mechanism.  Efficient detection of 
RNA splice variants may aid the identification of small molecules that modulate RNA splicing 
and accelerate biochemical studies of RNA splicing. 
 
4.1.2 In vitro and in-cell RNA splicing assays. 
 In vitro splicing assays have led to the discovery of many fundamental features and 
components of RNA splicing.7  Although the standard in vitro splicing system is limited by the 
fact that RNA splicing events are separated from transcription and translation, the versatility of 
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the assay has made it a powerful tool to dissect the mechanism of RNA splicing.  The major 
advantage of the in vitro splicing assay is its tremendous flexibility.  Biochemical approaches 
that modify the reaction conditions may lead to isolation, accumulation, and characterization of 
intermediates, which give valuable insight into how the splicing is accomplished as well as what 
regulatory factors are involved.  A typical in vitro splicing assay is carried out in nuclear extract, 
which contains the spliceosome and basic trans-acting factors for splicing.  The pre-mRNA of 
interest is prepared by in vitro transcription using radioactive nucleoside triphosphate–usually 
uridine triphosphate (UTP). The spliced products are separated and visualized by polyacrylamide 
gels and phosphorimagers analysis.7  
 In-cell splicing assays are crucial to understand the splicing mechansim in the natural 
context.  It has been found that the rate of intron removal is significantly slower in in vitro assays. 
And many RNA binding proteins that are involved in splicing, shuttle between the nucleus and 
cytoplasm.  Therefore in cell studies, which include the cytoplasm and other gene expression 
steps into account, provide a more accurate and complete picture of the splicing process.  Assays 
involve the isolation of RNA from the whole cell extract and measurement of mRNA by 
methods such as RT-PCR. 
 
4.1.3 High throughput screening methods  
 Small molecules provide a valuable tool to understand RNA splicing as well as other 
cellular processes.  For example, Spliceostatin A, which inhibits splicing and nuclear retention of 
pre-mRNA, has been used to reveal the functions of U1 snRNP's that are independent of 
splicing.8,9  Other small molecules that modify splicing patterns have been identified using 
several different strategies, including RT-PCR, reporters producing GFP, and luciferase.10-13  The 
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reporter constructs are designed by introducing an intron in the open reading frame so that only 
the spliced RNA will produce the reporter protein.  Each of these assays has limitations in a 
high-throughput setting.  RT-PCR cannot be easily scaled up and is costly.  The reporter systems 
assume the mRNA level is proportional to the expressed protein level, which may not be true in 
many cases.14  Another disadvantage of these methods is that it is hard to distinguish between 
compounds that modulate RNA splicing and those that affect transcription, or translation.14,15  
More sophisticated reporter constructs that overcome some of the limitations have been reported.  
However these reports recommend using RT-PCR or western blots to confirm that the obtained 
signal is proportional to the actual RNA splicing level.15    
 In vitro splicing assays may have some advantages over cell-based high throughput 
screening assays.  They do not involve the expertise in gene manipulation that is required to 
make the reporter construct and the reaction conditions can be easily modified.  However the 
detection step, which involves the use of radiolabeled RNAs and polyacrylamide gels, is the 
limiting factor for high-throughput in vitro splicing assays. 
 
4.1.4 Current methods to detect DNA and RNA 
 Although there are a limited number of reports that directly aim for the detection of RNA 
splice variants, there are several nucleic acid detection methods that can be adapted for RNA 
splicing assays.  Hybridization of nucleic acids has been utilized to develop such methods.  
Among those methods the most widely recognized is molecular beacons.  A molecular beacon is 
an antisense oligonucleotide probe that contains a fluorophore at one end and a quencher at the 
other end (Figure 4.2).  The probe forms a stem loop in the absence of the target nucleic acid, 
which brings the fluorophore and the quencher in close proximity.16  Encounter with the target 
nucleic acid separates the fluorophore from the quencher, which leads to an increase of 
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fluorescence.  Since the introduction of molecular beacons in 1996, many efforts have been made 
to improve their design and extend their applications.16  Currently, a large family of molecular 
beacons are used in many biological studies, including genetic screening, biosensor development, 
biochip construction, the detection of singlenucleotide polymorphisms (SNPs), and messenger-
RNA (mRNA) monitoring in living cells.16   
 
 
Figure 4.2 Molecular beacon.  Blue circle is the quencher and green star is the fluorophore. 
 
 Other antisense oligonucleotide based probes include quenched autoligation (QUAL) 
probes, quenched Staudinger-triggered α-azido ether release (Q-STAR) probes, and junction 
probes (see Figure 4.3 and 4.4 for the design of each probes).17-20  QUAL probes and Q-STAR 
probes rely on chemical reactions (SN2 reaction and Staudinger reaction, respectively) that are 
templated by the target nucleic acid.  QUAL probes are limited by slow reaction rate and 
undesired reactions with endogenous nucleophiles.17,19  Thus, Q-STAR probes, which utilize an 
orthogonal Staudinger reaction, were developed.19  Junction probe methods utilize two probes 
that do not hybridize, but can form a triplex with the target nucleic.  When the trimolecular 
nucleic acid forms, it presents a cognate restriction endonuclease site that is cleaved.  This 
cleavage reaction releases the quencher, which leads to fluorescence.20,21  The dissociation of the 
shortened probes and association of new probes amplifies the signal.  Although less simple 
compared to molecular beacons, the amplified signal is a significant advantage of QUAL, Q-
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STAR and the junction probes.  Further optimization may lead to promising probes that can be 
widely used. 
 
 
Figure 4.3 Nucleic acid detection probes developed by Kool et al.  a) QUAL probes. b) Q-STAR 
probes.  Blue circle is the quencher and green star is the fluorophore. 
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Figure 4.4 Junction probes. Red scissors indicate a restriction enzyme that is added to the 
solution. 
 
4.1.5 Biarsenical dyes and tetracysteine complex 
 In 1998, Tsien and co-workers introduced two cell permeable fluorogenic biarsenical 
dyes–4,5-bis(1,3,2-dithiarsolan-2-yl)fluorescein (FlAsH-EDT2) and 4,5-bis(1,3,2-dithiarsolan-2-
yl)resorufin (ReAsH-EDT2)–that bind to tetracysteine motifs for fluorescent protein labeling 
(Figure 4.5a and b).22  The biarsenical dyes are not fluorescent in the 1,2-ethanedithiol (EDT)-
bound form. When the dyes are incubated with a tetracysteine peptide that is separated by any 
two amino acids (Cys-Cys-X-X-Cys-Cys), EDT is exchanged for the tetracysteine motif and the 
complex fluoresces.  The biarsenical dye-tetracysteine complex is more than 50,000 times more 
fluorescent than FlAsH-EDT2.22  Tsien and co-workers hypothesized that the small size of EDT 
permits the rotation of the aryl-arsenic bond, which quenches the fluorescence by vibrational 
deactivation or photoinduced electron transfer.  In contrast, the aryl-arsenic bond of peptide 
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complex is more rigid, hindering the conjugation of the arsenic lone pair electrons with the 
fluorescein or resorufin orbitals, which allows the complex to fluoresce.22  The binding affinity 
of the FlAsH molecule and the tetracysteine peptide ranges from low pM to subnanomolar 
depending on the binding conditions and the identity of the amino acids in between the two 
dicysteine moieties.23 The sequence of FLNCCPGCCMEP was reported to have the lowest 
binding affinity for the FlAsH molecule and the highest quantum yield.23  This system was 
successfully used to fluorescently label proteins with a tetracysteine tag in vitro and in live 
cells.22,24,25 
 
 
Figure 4.5  a) Chemical structures of FlAsH-EDT2 and ReAsH-EDT2.  b) Fluorescent labeling of 
protein that contains tetracysteine motif.  c) Detection of peptide-peptide interaction using 
bipartite cysteine display. 
  
 More recently, this system was modified to detect protein-protein interactions and 
conformational changes of proteins.  Two peptides that contain dicysteine moieties at the end of 
each peptide were synthesized.  The peptide-peptide interaction brings the two bicysteine 
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moieties together forming the binding site for FlAsH molecule (Figure 4.5c).26  With the same 
split tetracysteine strategy, conformational change of a protein was also detected.27  The site to 
incorporate dicysteine motif was carefully selected and the fluorescence was monitored with the 
native protein and the denatured form of the protein.  Only the native protein that was folded 
correctly showed fluorescence.27 
  
 In this study, we have designed and analyzed a novel set of probes to detect RNA splice 
variants based on FlAsH and split tetracysteine motif.  Our results show that biarsenical dyes can 
bind to two dicysteine moieties that are brought together by complimentary oligonucleotides.  
The probes were able to detect nanomolar concentration of DNA and RNA transcripts suggesting 
the possibility of using these probes for a high throughput RNA splicing assay.   
 
4.2 Results & Discussion 
4.2.1 Design of the Probes 
 Biarsenical dyes 4,5-bis(1,3,2-dithiarsolan-2-yl)fluorescein (FlAsH-EDT2) and 4,5-
bis(1,3,2-dithiarsolan-2-yl)resorufin (ReAsH-EDT2) fluoresce upon binding to tetracysteine 
residues.  This method has been used to fluorescently label proteins and track them in living cells.  
Recently the Schepartz group26 and the Gierasch group27 reported a split tetracysteine strategy to 
study polypeptide and protein conformation.  They added two Cys pairs at the termini of a 
peptide or incorporated Cys residues within the β-sheet to create FlAsH binding sites when the 
peptide or protein was folded.   
Successful reconstitution of dye binding sites in the experiment described above 
suggested to us that this strategy could be used for the detection of RNA splicing following the 
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design shown in Figure 4.6. Thus, oligonucleotides that were complementary to two different 
exons were designed.  Dicysteine peptides ere attached to the 3’ or 5’end of the oligonucleotides 
such that the dicysteine groups would face each other when the oligonucleotides bound the target 
RNA splice variant.  Addition of FlAsH-EDT2 molecule should allow the detection of alternative 
splicing.  Compared to current methods such as RT-PCR and PAGE analysis with radiolabeled 
RNA, this method should be a more rapid and direct way to monitor splicing.  In addition, this 
method could be an efficient high throughput screening method for detecting small molecules 
that activate or repress alternative splicing. 
   
 
Figure 4.6 Detection of RNA splice variants using FlAsH and dicysteine conjugated antisense 
oligonucleotide probes. 
  
 For the splicing system, the human survival motor neuron (SMN) gene was chosen.  Pre-
mRNA splicing of SMN1 includes exon 7, which is translated into a functional SMN protein.  An 
extra copy of SMN gene, designated SMN2 has a critical C to T transition within the exonic 
splicing enhancer site.  This transition abrogates the binding of trans-acting splicing factor 
SF2/ASF, which results in an unstable exon 7-skipped protein isoform (Figure 4.7).28,29  Spinal 
	   116	  
muscular atrophy is caused by the loss of function of both copies of SMN1 genes.30-32  Therefore 
this system has been studied intensively to restore the ability of SMN2 gene to include exon 7 to 
form a functional SMN protein.33  Quantitative detection of these two isoforms would facilitate 
the efficiency of these studies. 
 
 
Figure 4.7 Expression of SMN1 and SMN2 genes.  SMN2 gene has a T instead of C in exon 7, 
which results in a low level of SMN proteins.29   
 
 For the detection of two different splice variants of SMN RNA, two antisense 
oligonucleotide probes that are each complimentary to exon 7 and exon 8 were designed (Figure 
4.8).  When exon 7 is included in the splice variant, both probes may bind to the transcript 
positioning the two dicysteine moieties in proximity.  Then FlAsH-EDT2 should bind to the two 
dicysteine moieties, which will result in fluorescence.  On the other hand, when exon 7 is 
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excluded, the exon 7 probe cannot be in proximity of the exon 8 probe therefore, resulting in no 
fluorescence.  Previous studies have shown that the two dicysteine moieties need to be within 7Å 
for the FlAsH molecule to effectively bind the split tetracysteine.26  Therefore, a maleimide 
linker was selected due to its short length and ease of synthesis.34  Based on computational 
analysis with the program Molecular Operating Environment (MOE), the two probes were 
designed so that there would be no space between the two probes when annealed to the target 
RNA.  This allowed the two dicysteine peptides to be positioned within 7Å of each other. 
 
 
Figure 4.8 Sequences of the two probes and the chemical structure of the linker. 
 
Scheme 4.1 Synthesis of GCC-linker.  
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4.2.2 Synthesis of the Probes 
 The maleimide containing dicysteine peptide was prepared on solid support using 
standard coupling reagents (Scheme 4.1).  An orthogonal protecting group of the cysteine 
residues, which is not cleaved during the resin cleavage is critical since the maleimide reacts 
with thiol groups.  Tert-thiol butyl group suited this requirement and can be easily deprotected 
using dithiothreitol (DTT).  The thiol groups of DNA antisense oligonucleotides were 
deprotected using DTT and allowed to react with the maleimide groups of the dicysteine peptides.  
The final product was obtained by deprotecting the cysteines (Scheme 4.2).  
 
Scheme 4.2 Synthesis of both probes. 
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4.2.3 Detection Limit of Biarsenical Tetracysteine and FlAsH-EDT2 System 
 For RNA splicing assays, a high detection limit is required.7 A typical FlAsH, 
tetracysteine tagged protein experiment uses low concentrations of FlAsH-EDT2 and an excess 
of the protein.  This is optimal for the detection of protein since the binding affinity of FlAsH 
and the peptide tag is in the low picomolar range and the low concentration of FlAsH reduces the 
background fluorescence of FlAsH-EDT2.  However the bipartite cysteine display experiments 
have shown that the binding affinity between the split tetracysteine motif and the FlAsH 
molecule is in the low micromolar range.26,27  Therefore, in order to detect a low concentration of 
RNA splice variants and considering the fact that the binding affinity of the split tetracysteine 
motif is lower than that of intact tetracysteine motif, a higher FlAsH-EDT2 concentration is 
required.  In addition to the FlAsH-EDT2 concentration, EDT concentration is an important 
factor to obtain good signal to noise ratio since the equilibrium of the fluorescence reaction, 
FlAsH-EDT2 + peptide  FlAsH-peptide + 2 EDT depends on the concentration of EDT.  Low 
concentrations of EDT favor the FlAsH-peptide product but also increases the noise due to non-
specific binding.  Thus two factors, FlAsH-EDT2 and EDT concentrations were considered for 
the optimization of conditions in the following experiments.  
 First the detection limit of the tetracysteine peptide and FlAsH system was assessed with 
1 µM FlAsH-EDT2.  At 10 µM concentration of EDT, a linear increase of the fluorescent signal 
was observed when the concentration of the peptide increased from 10 nM to 50 nM (Figure 
4.9a).   However at concentrations lower than 10 nM, it became difficult to distinguish between 
the concentrations of the peptide based on fluorescence signal (Figure 4.9b).  These results show 
that the detection limit of FlAsH and tetracysteine system is in the low nanomolar range.  
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Figure 4.9 Detection of positive control peptide (FLNCCPGCCMEP). Binding reactions were 
performed using 1 µM FlAsH-EDT2, in 100 mM Tris-HCl (pH 7.4) containing 3.5 mM TCEP, 
10 µM EDT. 
 
4.2.4 Detection of SMN DNA 
 Before evaluating the detection of RNA with the designed system, DNA was evaluated in 
order to optimize the conditions because DNA is more stable and costs less than RNA.  The 
probes were tested with a 50-mer DNA that contains a sequence encompassing exon 7 and exon 
8 (Figure 4.8).  To verify that the FlAsH molecule can bind to the designed probes when 
annealed to the target DNA, I used high concentrations of both probes and target DNA.  1 µM of 
target DNA was detected using 1 µM of each probes and 25 nM FlAsH-EDT2 and 10 µm EDT.  
Within 10 minutes, ~9 fold higher fluorescence was observed in the presence of target DNA, 
FlAsH-EDT2 and the probes compared to the FlAsH only sample.  The fluorescence was 
measured up to 1 hour, and the fluorescence of the solution that contains the target DNA 
continuously increased.  One concern for the experiment was the background fluorescence from 
the non-specific binding of FlAsH to the probes.  Therefore, the signal to noise ratio was 
calculated as the fluorescence intensity of the solution that contained the target DNA, FlAsH-
EDT2, and probes versus the fluorescence intensity of the solution that contained FlAsH-EDT2 
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and the probes.  The signal to noise ratio was highest before 10 minutes and then gradually 
decreased. 
 
 
Figure 4.10 FlAsH fluorescence experiments detecting 1 µM target DNA. a) Fluorescence 
intensity after 10 minutes of reaction time.  b) Kinetics of the reaction measured 2 minutes after 
mixing and up to 2 hours.  "FlAsH only" is a solution containing just the FlAsH-EDT2.  "Probes" 
solution contains FlAsH-EDT2 and both probes.  "With target" solution contains FlAsH-EDT2, 
both probes and the target DNA. Error bars represent SD of triplicates. 
 
 Experiments at different concentrations of FlAsH-EDT2 and EDT were performed 
(Figure 4.11 and 4.12).  For all the fluorescence experiments, the target DNA was added first, 
followed by the probes and then FlAsH-EDT2.  50 nM concentration of target DNA was detected 
with 50 nM of each probe and different FlAsH concentrations.  The signal to noise ratios at 1 µM 
FlAsH and 100 nM FlAsH are both 2.1.  As the FlAsH concentration was decreased further the 
signal to noise ratio went down and at 1 nM FlAsH concentration the probe signal was higher 
than the solution that contained the target DNA.  1 µM FlAsH was chosen for further studies 
because the signal to noise ratio was highest under these conditions and the background 
fluorescence of the probes compared to the FlAsH only solution was lowest.  In contrast to 
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FlAsH, the concentration of EDT did not have a significant effect on the signal to noise ratio.  At 
four different concentrations of EDT the signal to noise ratio ranged from 2.1 to 2.4 (Figure 
4.12). 
 
 
Figure 4.11  FlAsH fluorescence experiments at different concentrations of FlAsH-EDT2:  a) 1 
µM, b) 100 nM, c) 10 nM and d) 1 nM.  The EDT concentration was 10 µM for all experiments. 
Error bars represent SD of triplicates. 
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Figure 4.12  FlAsH fluorescence experiments at different concentrations of EDT. Error bars 
represent SD of triplicates.   
 
 
Figure 4.13 Detection of different concentrations of target DNA.  FO is FlAsH only.  Error bars 
represent SD of triplicates. 
 
 The ability of these probes to detect different concentrations of the target DNA was 
assessed.  Concentrations ranging from 10 nM to 50 nM with 10 nM increments were detected 
(Figure 4.13).  The fluorescence intensity corresponds to the concentration of the target DNA.  
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However at 40 nM the fluorescence intensity saturated.  Thus, careful adjustment of the 
concentration of the probes is required to quantitatively detect the target DNA.  
 
4.2.5 Detection of SMN RNA transcript 
 In order to test if the probes and the FlAsH molecule can detect two different RNA splice 
variants, SMN 678 and SMN 68 were studied.  Plasmid DNAs that contain two different splice 
products of the SMN2 gene were transcribed and their sizes confirmed by denaturing gel 
electrophoresis with RNA size markers. These transcripts were tested with the same buffer 
conditions used for DNA detection using the 50-mer SMN DNA as a comparison.  As shown in 
Figure 4.14, the probes were able to detect the SMN 678 transcript within an hour with slightly 
lower signal to noise ratio than the 50-mer SMN DNA.  Whereas, the fluorescent intensity of the 
other splice product, SMN 68 did not increase above the background level.  A kinetic analysis 
performed over 13 hours is shown in Figure 4.14a and the corresponding signal to noise ratio is 
shown in Figure 4.14b.  After 13 hours, SMN 678 transcript and 50-mer SMN DNA showed 15-
fold and 12-fold increase in fluorescence respectively. The signal to noise ratio reached a 
maximum at 4 hours and decreased over time.  A decrease in the signal to noise ratio over a 
longer period of time may be due to non-specific binding of the FlAsH molecule to the 
dicysteine probes and degradation of FlAsH in aqueous solution.  The 50-mer SMN DNA, 
compared to SMN 678 RNA transcript, shows a faster increase in fluorescence thus resulting in a 
higher signal to noise ratio up to 7 hours.  There are two differences between the DNA detection 
and the RNA transcript detection.  The target DNA forms a DNA-DNA duplex while the target 
RNA forms a RNA-DNA duplex, and the SMN 678 RNA transcript (299 nucleotides) is longer 
than the short 50-mer DNA target.  The RNA transcript may form a secondary structure that 
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increases the reaction time and reduces the signal to noise ratio.   The same experiment was 
performed at a higher EDT concentration to decrease the background fluorescence due to non-
specific binding (Figure 4.15).  However, for both 50-mer DNA and SMN 678 RNA, the extent 
of fluorescence decrease due to the higher EDT concentration exceeded the effect of lower 
background signal.  Thus, reduced signal to noise ratios were observed.   
  
 
Figure 4.14 Detection of SMN RNA transcripts and 50-mer SMN DNA at 10 µM EDT.  a) 
Kinetic analysis of the detection.  b) Signal to noise ratios at different times.  Fluorescence 
intensity of each solution after c) 1 h and d) 4 h of reaction time.  Error bars represent SD of 
triplicates. 
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Figure 4.15 Detection of SMN RNA transcripts and 50-mer SMN DNA at 1 mM EDT.  a) 
Kinetic analysis of the detection.  b) Signal to noise ratio at different times.  Error bars represent 
SD of triplicates. 
 
 
Figure 4.16  Detection of varied ratios of SMN 678 and SMN 68 RNA.  The P value (student t-
test) between 60/40 and 40/60 is less than 0.05.  Error bars represent SD of triplicates. 
 
 To find small molecules that may increase or decrease an RNA splice variant, the probes 
need to detect different ratios of the two alternative splice products.  SMN 678 RNA and SMN 68 
RNA ratio was varied and the probes and FlAsH-EDT2 were added.  As shown in Figure 4.16, 
the probes were able to distinguish between "high" and "low" ratios but were not able to 
precisely distinguish each ratio.    
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4.2.6 ReAsH Fluorescence Experiments 
 ReAsH emits away from the blue and green zone of spectrum in which many cells 
autofluoresce.  Thus, for cell studies, ReAsH has an advantage over FlAsH.  ReAsH-EDT2 was 
synthesized and quality control experiments were performed as previously described by Adams 
et al.35  Although the ESI-TOF result and NMR confirmed the product compound, a standard 
1000-fold increase in fluorescence upon the addition of the control peptide was not observed.  
Instead a maximum of 152-fold increase in fluorescence was obtained.  I proceeded with this 
ReAsH-EDT2 compound to observe the signal change with the probes and target DNA.  An 
approximately 2-fold increase in fluorescence in the presence of 200 nM target and probes was 
observed and a slightly higher fluorescence increase with the control peptide (2.6-fold) (Figure 
4.17).  This indicates that these probes could be used with ReAsH and is not limited to FlAsH.  
However experiments need to be repeated with higher quality ReAsH-EDT2 to further confirm 
this preliminary data. 
 
 
Figure 4.17 Detection of target DNA with ReAsH.  The final concentration of each components 
were 1µM ReAsH-EDT2, 200 nM target DNA, and 200 nM probes. 
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4.3 Conclusion 
 A set of novel nucleic acid detection probes were designed, synthesized and characterized.  
This method includes the use of biarsenical dye compounds and two antisense oligonucleotides 
that contain dicysteine moiety at the 3' or 5' end.  Fluorescence increase upon addition of target 
nucleic acid shows that FlAsH compound can efficiently bind to split dicysteine moieties that are 
brought together by annealing of two antisense oligonucleotides to a target nucleic acid.  The 
probes are capable of detecting micromolar concentration of DNA in less than 10 minutes and as 
low as nanomolar concentrations of RNA in an hour of reaction time.  The signal to noise ratio 
reached its maximum in 4 hours for both DNA and RNA. Although the probes were not able to 
accurately distinguish between each concentration, they were able to report "high" or "low" 
concentration.  Careful control of the concentration of the probes may give more quantitative 
results.  Due to the ease of design and synthesis of these probes, they may potentially be used in 
high-throughput screening assays to identify small molecule modulators of RNA splicing. 
 
4.4 Materials and Methods 
Materials 
 All DNAs and RNAs were purchased from Integrated DNA technology (IDT) and were 
purified by HPLC or PAGE. All solvents were obtained from Fisher Scientific.  The 
trifluoroacetic acid (TFA), mercuric oxide (HgO), 2-(N-morpholino)ethane-sulfonic acid (MES), 
piperidine, 2,4,6-collidine and ethane dithiol (EDT) were obtained from Sigma-Aldrich.  Fmoc-
Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Cys(StBu)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-
Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Tyr-OH), coupling reagents, and resins 
were purchased from Chem Impex or Novabiochem.  
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Synthesis and quantification of FlAsH-EDT2 and ReAsH-EDT2 
 FlAsH-EDT2 and ReAsH-EDT2 were synthesized and purified as previously described.35 
The final product was dissolved in DMSO.  The concentration of the DMSO stock solution was 
determined by diluting the sample into a 0.1 M NaOH solution.  The UV absorption was 
measured at 496 nm for FlAsH-EDT2 and 579 nm for ReAsH-EDT2 and the concentration was 
calculated using the extinction coefficients reported previously: 69,500 M-1cm-1 and 63,000 M-
1cm-1 respectively.  The DMSO stock was aliquoted and stored at -20 °C covered in foil to 
protect the sample from light. 
 
Sequences of the oligonucleotides used in this study are listed. 
Exon 7 probe: 5’-TCCTTAATTTAAGGAATGTG-3’ 
Exon 8 probe: 5’-CTCTATGCCAGCATTTC-3’ 
50-mer SMN 78 DNA:  
5'-GTGCTCACATTCCTTAAATTAAGGAGAAATGCTGGCATAGAGCAGCACTA-3' 
SMN2 678 RNA transcript: 
CCCGAGAUUCCCCCACCACCUCCCAUAUGUCCAGAUUCUCUUGAUGAUGCUGAUG
CUUUGGGAAGUAUGUUAAUUUCAUGGUACAUGAGUGGCUAUCAUACUGGCUAUU
AUAUGGGUUUCAGACAAAAUCAAAAAGAAGGAAGGUGCUCACAUUCCUUAAAUU
AAGGAGAAAUGCUGGCAUAGAGCAGCACUAAAUGACACCACUAAAGAAACGAUC
AGACAGAUCUGGAAUGUGAAGCGUUAUAGACGAUAACUGGCCU 
 
SMN2 68 RNA transcript: 
CCCGAGAUUCCCCCACCACCUCCCAUAUGUCCAGAUUCUCUUGAUGAUGCUGAUG
CUUUGGGAAGUAUGUUAAUUUCAUGGUACAUGAGUGGCUAUCAUACUGGCUAUU
AUAUGGAAAUGCUGGCAUAGAGCAGCACUAAAUGACACCACUAAAGAAACGAUC
AGACAGAUCUGAAUGUGAAGCGUUAUAGACGAUAACUGGCCU 
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Synthesis of the maleimide linker 
 
N-glyclylmaleimide was synthesized as previously described.34  
 
Fmoc solid phase peptide synthesis (SPPS) 
 Control peptide (YFLNCCPGCCMEP), negative control peptide (GCCMEPY) and the 
dicysteine peptide (GCC) were manually synthesized using standard Fmoc solid-phase peptide 
synthesis.36  Fmoc-amino acid (3 eq to resin loading) and HCTU (3 eq) were dissolved in DMF 
(4 mL), and to this solution NMM (5 eq) was added and pre-activated for 5 min.  The activated 
amino acid solution was transferred to pre-swelled resin and reacted for 2 h.  The completion of 
couplings was confirmed by a negative Kaiser test.  The subsequent removal of Fmoc group was 
done using 20% piperidine in DMF.  Resin, trityl group and OtBu group were removed 
simultaneously by treatment with a cocktail containing TFA/TIS/H2O (95:2.5:2.5).  For the GCC 
peptide, the maleimide linker was coupled using the same coupling conditions described above 
before the cleavage of the resin.  All the peptides were purified by reverse phase HPLC using a 
semi-preparative C18 column (Vydac Protein & peptide C18 (218TP1010), 10 µm, 10 x 250 
mm).  HPLC method: Flow rate 2 mL/min, detection at 245 nm. Gradient: Starting from 10% 
MeCN the concentration of MeCN was increased to 80% over 40 min, 80% MeCN was held 
steady for 60 min. followed by ramping down to 10% MeCN over 10 min.  The StBu groups of 
the control peptide and the negative control peptide were deprotected in a solution of DMF/0.1M 
ammonium bicarbonate with 20 equiv. of DTT at room temperature overnight. The pH of the 
reaction mixture was adjusted to 2 with acetic acid and was purified directly by reverse phase 
N
O
O
HO
O
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HPLC using the same HPLC method described above.  The fractions containing the product 
were concentrated in vacuo and lyophilized.  The identities of the positive and negative control 
peptides were confirmed with low resolution MALDI-TOF and the identity of the dicysteine 
peptide was confirmed with low resolution ESI-TOF.  
Positive control peptide (M+H+): Calculated 1480.8, found 1480.2. 
Negative control peptide (M+H+): Calculated 802.9, found 801.5. 
GC(StBu)C(StBu)-L peptide (M+H+): Calculated 595.8, found 595.3. 
 
Synthesis of the probes 
 The thiol protecting group of the ordered antisense DNA was removed in a solution of 
TE buffer (pH 8.0) with 100 mM DTT for 4h or overnight.  The deprotected oligonucleotide was 
purified using amicon® ultra centrifugal filters (MWCO 3000).  The reaction mixture was added 
to the filter and was centrifuged for 40 min. Autoclaved water was added to the filter and 
centrifuged again for 40 min.  This was repeated at least three times.  In the last round 
centrifugation, 0.1 M TTEA buffer was added instead of water for the next reaction.  The 
purified solution of DNA and 10-fold excess of the maleimide linker coupled GCC peptide were 
allowed to react at room temperature in 1 mL of 20% 0.1 M TEAA/acetonitrile overnight under 
nitrogen.  The resulting product was again purified using amicon® ultra centrifugal filters 
(MWCO 3000) as decribed above.  The last round of purification was performed with TE buffer 
(pH 8.0).  The StBu groups were deprotected in a solution of TE buffer (pH 8.0) with 100 mM 
DTT overnight.  The deprotected StBu groups and excess of DTT were removed with amicon® 
ultra centrifugal filters (MWCO 3000).  The concentration of the final product was determined 
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using UV spectroscopty and the extinction coefficient of the DNA was provided by the 
manufacturer.  The probes were confirmed with ESI-TOF.  
 
Transcription of SMN 68 and SMN 678 
 Plasmid DNAs that encode SMN2 exon 678 and SMN2 exon 68 were each ordered from 
IDT.  The sequences of the two pDNAs were confirmed at University of illinois at Urbana-
Champaign sequencing center.  SMN plasmid DNAs were linearized for transcription using 
restriction enzyme, Not I (Invitrogen) in a total of 20 µL buffered solution provided by the 
manufacturer.  The reaction was left overnight at 37 °C for complete cleavage.  The cleaved 
products were purified by running an agarose gel and extracting the bands using a gel extraction 
kit (Qiagen).  The linearized plasmid DNAs were transcribed following the MEGAScript 
(Ambion) instructions.  The transcripts were confirmed using a 5% denaturing polyacrylamide 
gel (8.3 × 7.3 cm).  The gel was pre-ran at 100 V and the samples and RNA markers (RNA 
CenturyTM Plus Markers, Ambion) were ran at 80 V for 90 min.  
 
Figure 4.18 Denaturing PAGE of SMN 678 and SMN 68 RNA transcripts. M is marker, lane 1 is 
SMN 678, and lane 2 is SMN 68. The numbers on the left side of the RNA marker lane are the 
number of nucleotides. 
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General procedure for fluorescence experiments 
 TTEM buffer (100 mM Tris-HCl, 3.5 mM TCEP, 10 µM EDT, and 10 mM MgCl2) was 
freshly prepared for each experiment from the following stock solutions: 1M Tris-HCl (pH 7.4), 
0.5 M TCEP, 10 mM EDT, 1M MgCl2.  The 10 mM EDT solution was prepared fresh for each 
experiment by adding 0.84 µL of EDT into 1 mL of dry DMSO.  Typically 2~4 mL of TTEM 
buffer was made and was degassed by vacuum sonication for 20 min.  In a 384 well plate, the 
buffer was added followed by the probes and the target nucleotide.  FlAsH-EDT2 was added last 
and the solution was left at room temperature covered with an aluminum foil for indicated 
amount of time.  For longer incubation times (> 2h), the plates were sealed to prevent 
evaporation of the solution. 
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